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Prefácio 
 
 Nesta dissertação apresentam-se os resultados do trabalho desenvolvido 
entre Setembro de 2007 e Maio de 2011, no Laboratório de Fisiologia Celular e 
Imunologia (Rockefeller University, New York, New York, USA) sob a orientação 
do Professor Doutor Ralph M. Steinman (supervisor internacional), e tendo como 
supervisor nacional o Professor Doutor Luís Graca. 
 Este trabalho teve como principal objectivo a produção de anticorpos 
monoclonais contra a letina DC-SIGN/CD209a do rato. Este reagente foi 
importante para a identificação e caracterização de um novo subtipo de células 
dendriticas que se diferenciam a partir de monócitos do sangue em resposta ao 
LPS (lipossacarídeo) um constituinte da parede celular de bactérias gram-
negativas.  
 A presente dissertação encontra-se dividida em 7 capítulos: Introduction, 
onde se encontram resumidos os conhecimentos até à data acerca das células 
dendriticas, suas funções, principais subtipos e receptores que expressam para 
reconhecimento de patógenes e onde focamos a abordagem na lectina do tipo C 
denominada DC-SIGN/CD209a; Experimental procedures, com a descrição dos 
métodos e reagentes utilizados durante a investigação levada a cabo neste 
estudo; Results, onde são apresentados todos os resultados originais obtidos 
neste estudo, parte dos quais são apresentados também na forma de artigos no 
último capítulo. Discussion, onde são discutidos detalhadamente os resultados 
obtidos, Conclusion and Future Perspectives com as conclusões a que permitiu 
chegar este estudo e onde são também apresentadas perspectivas de 
investigação futura;  References, onde são enumeradas as publicações 
consultadas durante a elaboração desta tese. Finalmente, Publications, onde 
constam os artigos publicados em revistas científicas durante o período de 
execução da presente dissertação. 
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 De acordo com o disposto no artigo 40° do Regulamento de Estudos Pós-
Graduados da Universidade de Lisboa, Deliberação n°961/2003, publicada no 
Diário da República – IIa Série, n° 153 de 5 de Julho de 2003, foram incluídos 
nesta tese resultados dos artigos abaixo indicados: 
Manuscripto 1. Cheong C, Matos I, Choi JH, Schauer JD, Dandamudi DB, 
Shrestha E, Makeyeva JA, Li X, Li P, Steinman RM, Park CG. New monoclonal 
anti-mouse DC-SIGN antibodies reactive with acetone-fixed cells. 2010 Aug 31. J 
Immunol Methods. 360(1-2):66-75.  
 
Manuscripto 2. Cheong C*, Matos I*, Choi JH, Dandamudi DB, Shrestha E, 
Longhi MP, Jeffrey KL, Anthony RM, Kluger C, Nchinda G, Koh H, Rodriguez A, 
Idoyaga J, Pack M, Velinzon K, Park CG, Steinman RM.. Microbial stimulation 
fully differentiates monocytes to DC-SIGN/CD209(+) dendritic cells for immune T 
cell areas. 2010 Oct 29. Cell. 143(3):416-29. *NOTE: Equal contribution. 
 
 No cumprimento do disposto na referida deliberação, a autora esclarece 
serem da sua inteira responsabilidade, excepto quando referido em contrário, a 
execução das experiências que levaram aos resultados apresentados nesta tese 
assim como a interpretação e discussão dos mesmos. Resultados obtidos por 
outros autores foram tambem incluidos com autorização dos mesmos, de forma 
a facilitar a compreensão dos trabalhos e estão devidamente assinalados nas 
respectivas figuras. 
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Resumo 
 As células dendríticas (DCs) desempenham um papel fundamental na 
regulação da resposta imunitária pela sua eficiência na apresentação de 
antigénios. Sabe-se que as células dendriticas derivam de precursores da 
medula óssea, mas o seu potencial para se desenvolverem directamente a 
partir de monócitos em circulação no sangue nunca foi devidamente 
demonstrado in vivo. 
 Neste estudo provamos que a diferenciação de DCs pode ocorrer a partir 
de monócitos (Mo-DC, de “monocyte-derived DCs”) no murganho. Estas Mo-
DCs caracterizam-se pela expressão de CD209a, também designada como DC-
SIGN, uma proteína da família das lectinas do tipo C. Células que expressam 
esta proteína são encontradas nos nódulos linfáticos após a injecção de 
lipossacarídeo (LPS) purificado ou de bactérias gram-negativas. Mostrámos 
ainda que a mobilização destas Mo-DCs requer a presença dos receptores TLR4 
e CD14 e da proteína intracelular Trif. 
 As células Mo-DCs descritas neste trabalho apresentam uma morfologia 
típica de DCs e localizam-se nos nódulos linfáticos na área das células T. Esta 
localização está de acordo com sua função na apresentação de antigénios, que 
inclui a apresentação cruzada de antigénios associados a moléculas de MHC 
classe I. Foi ainda demonstrado que a mobilização das células Mo-DCs in vivo 
depende da expressão da molécula de adesão L-selectina e da quimoquina 
CCR7.  
 Em resumo, este trabalho mostra pela primeira vez que monócitos 
presentes no sangue se podem diferenciar em células dendríticas. Este 
processo de diferenciação ocorre em resposta à presença de LPS, um 
componente da parede celular de bactérias Gram-negativas, e involve a 
aquisição de diversas características tipicamente associadas a DCs. Esta nova 
sub-polulação de DCs é também caracterizada pela expressão da proteína 
CD209a.  
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Abstract 
 
 
Dendritic cells (DCs), critical antigen-presenting cells for immune 
control, normally derive from bone marrow precursors distinct from 
monocytes. It is not yet established if the large reservoir of monocytes 
can develop into cells with critical features of DCs in vivo. We now show 
that fully differentiated monocyte-derived DCs (Mo-DCs) can develop in 
mice and are marked by the C-type lectin DC-SIGN/CD209a. Here, we 
report that Mo-DCs are recruited from blood monocytes into lymph nodes 
by lipopolysaccharide (LPS) and live or dead gram-negative bacteria. 
These Mo-DCs mobilization requires TLR4 and its CD14 coreceptor via a 
Trif dependent signaling pathway. When tested for antigen-presenting 
function, Mo-DCs are as active as conventional DCs, including cross-
presentation of antigens of proteins or live gram-negative bacteria on 
MHC I. Fully differentiated Mo-DCs acquire DC morphology and localize to 
T cell areas via the adhesion molecule L-selectin and the chemokine 
CCR7. Thus the large reservoir of blood monocyte can become the 
dominant presenting cell in response to select microbes, acquire the 
expression of DC-SIGN and other critical features of DCs. 
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Chapter 1. Introduction 
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A. The Immune System 
 The vertebrate body is constantly challenged by a variety of pathogens, 
such as viruses, bacteria, fungi and parasites. In order to respond to this 
constant threat, vertebrates have evolved an elaborate immune system that, in 
many cases, confers protective immunity to disease-causing microorganisms.  
 The immune system is commonly divided into two major branches: innate 
and adaptive immunity (Janeway, 2006). 
 At the primary stage of any infection, our immune system initially relies on 
the quick but unspecific defenses that constitute innate immunity. Innate 
immune responses involve both soluble and germline-encoded cell surface 
receptors that recognize a finite set of molecular patterns associated with tissue 
damage and certain pathogens (Janeway and Medzhitov, 2002). 
 Dendritic cells (DCs) form an integral part of this innate immune system, 
supported by the activity of other bone marrow derived non-specific immune cells 
– such as mast cells, natural killer cells, granulocytes and other phagocytes like 
monocytes or macrophages – and various resident tissue cells, including 
epithelial cells. These innate immune cells respond rapidly to invading 
microorganisms in the mucosa and other exposed tissues, releasing 
inflammatory cytokines that recruits effector cells and initiate antimicrobial 
activity. 
 Innate immunity is still considered to lack specific memory, which is a 
primarily feature of the adaptive immune system (Janeway, 2006) and therefore, 
repeated exposure to the same pathogen does not substantially alter the nature 
of the ensuing response.  
 Adaptive immunity takes longer to develop and is conveyed by two main 
types of lymphocytes: B cells, which mature in the bone marrow and are 
responsible for humoral-mediated immune responses, and T cells, which mature 
in the thymus and are involved in cell-mediated immunity. 
 Adaptive immune responses can provide long-lasting protection against 
reinfection and are highly specific for a particular pathogen. Once activated 
lymphocytes must first undergo clonal expansion before they differentiate into 
! "(!
effector cells and be able to clear the infection. Memory B and T cells mount 
strong immune responses that are qualitatively and/or quantitatively enhanced at 
a second encounter with a certain pathogen. Moreover, the versatility of adaptive 
responses is almost unlimited with regard to antigen specificity. A principal 
mechanism generating this diversity is the random recombination of variable, 
diversity and joining gene segments (VDJ) during lymphocyte development, 
which depends on the synergistic activity of proteins encoded by recombination-
activating gene 1 (Rag1) and Rag2 and gives rise to millions of naive T cells and 
B cells, each with a unique antigenic specificity. This complex combinatorial 
diversity allows the human immune system to make potentially 1011 different 
receptors expressed on B cells and 1018 different T cells (Janeway, 2006), 
although the actual number of distinct receptors present in the body at any given 
time is far less than this. Adaptive immune responses finally rely on the presence 
of these rare B and T cells specific for a certain invading pathogen.  
 
B. Dendritic Cells 
 Until 1973, the year in which dendritic cells were discovered, the link 
between innate and adaptive immune system was not accurately understood. At 
the time, the induction of immune responses in the lymphoid organs was 
believed to require both lymphocytes and a yet uncertain type of “accessory 
cells” though to be typical macrophages (Mosier, 1967).  
 Steinman and Cohn were working on macrophages as a model to study 
immune responses initiation. They found that these cells could not keep whole 
antigens on the cell surface but simply degraded it and were therefore unable to 
present them to lymphocytes. Steinman decided then to leave peritoneal 
macrophages beyond and look at mouse splenocytes, since previous work 
supported the presence of a pool of splenic accessory cells required for the 
generation of in vitro primary antibody responses (Mishell and Dutton, 1966; 
Mosier, 1967). When looking at these accessory cells in the culture dish and 
using phase-contrast light microscopy, the investigators found a small number of 
! "*!
extensively branched, motile and mitochondria-rich cells mixed in and different 
from any other immune cell so far described. Because of their unique 
morphology with the tree-like processes, Steinman and Cohn named them 
“dendritic cells” (DCs) from the greek word dendron, or tree (Steinman and Cohn, 
1973). 
 
1. DC features 
With the development of new protocols to isolate and purify DCs from the 
mouse spleen (comprising ~1% of the total cells in this organ), it was possible to 
begin the functional studies (Steinman et al., 1975; Steinman and Cohn, 1973; 
Steinman and Cohn, 1974; Steinman et al., 1979; Steinman et al., 1974; 
Steinman and Witmer, 1978). Although current understanding of the biology of 
DCs is still expanding, in the following sections I will talk about some important 
features so far ascribed for these cells. 
 
 1.1. Potent antigen presenting cells 
 Steinman and colleagues soon noticed that this new type of cells expresses 
very high levels of the surface antigen MHC class II (Steinman et al., 1979). This 
observation led them to test if DCs could then induce a so-called mixed leukocyte 
reaction (MLR) (Steinman and Witmer, 1978), a clinical model for graft rejection 
to identify the degree of compatibility of tissue transplants between donors and 
recipients. In the MLR, leukocytes from one individual, the potential transplant 
donor, are mixed with T cells from the responder or graft recipient. If donor and 
recipient are mismatched at the MHC, the T cells begin to proliferate whereas 
those from compatible individuals will not. Before the discovery of DCs, the assay 
was known as the mixed “lymphocyte” reaction, because it was presumed that 
the B lymphocytes were presenting MHC products from the organ transplant 
donor to the recipient’s T cells (Lonai and McDevitt, 1974). However, the results 
obtained by Steinman and colleagues showed that purified DCs were an 
impressive 100-fold better at activating T cells in the mix compared with 
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macrophages or B cells, and were more potent than bulk spleen cells. In this 
regard, only 1 DC can turn on 100-3.000 T cells whereas activation of T cells by 
Macrophages and B cells is weak even at a 1:1 cell ratio (Steinman and Witmer, 
1978). 
 Since these early years of DC research, several studies have proved that 
DCs are the most specialized antigen-presenting cell (APC) and are unique 
among all APCs because they have the capacity to initiate cellular immunity.  
 But before DCs can perform their major function—to initiate the immune 
response—two events typically need to take place: migration and maturation.  
 
 1.2. DC migration 
 Most DCs circulate in the body in an "immature" state and lack many 
features that lead to T-cell activation. Nonetheless, immature DCs act as 
“immunological sentinels”, continuously circulating through peripheral and 
lymphoid tissues where they capture microbes and other sources of antigens. 
Thus, they are stationed at surfaces where antigens gain access to the body. For 
example, they can be found in the epithelial of the skin where they are termed 
Langerhans cells (Schuler and Steinman, 1985). DCs are also located in the 
afferent lymphatic vessels, which allow cells to move from peripheral tissues to 
lymphoid organs. There they can encounter naïve lymphocytes, selecting those 
cells that specifically recognize the antigens being carried by the DCs (Randolph 
et al., 2005). At this point the immune response begins. 
 The “migration” process occurs at a basal rate in the steady-state (Henri et 
al., 2001; Kissenpfennig et al., 2005) but is enhanced during inflammation 
(Cumberbatch et al., 1997; Jakubzick et al., 2008; Roake et al., 1995). On 
exposure to immune or inflammatory signals, DCs undergo functional maturation 
and reenter the circulatory system to home to the T cell areas of lymphoid 
organs. To do so, two routes are so far described, via the lymphatic vessels to 
reach the lymph nodes or through the blood to reach the spleen.  
 Cell migration involves the coordinate activation of two classes of effector 
molecules, adhesion molecules and chemotactic factors.  
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 Adhesion molecules, such as CD62L, CD49d, CD44 and CLA, mediate 
binding to endothelial cells found lining the lymphatics and blood vessels, and at 
the same time these adhesion molecules regulate the interaction of the migrating 
cells with the extracellular matrix (Sozzani et al., 1999).  
 Chemokines are a much complex group of molecules. This protein 
superfamilly includes about 50 different members that can be classified into four 
groups according to the position of the N-terminal cysteines. Virtually all cell 
types produce chemokines under appropriate conditions of stimulation. The 
stimuli and the cellular context dictate the pattern of chemokine production. For 
instance, certain chemokines have different or divergent effects with regard to 
the target cell and the chemokine considered.  
 Chemokines evoke their biological functions by interacting with specific 
chemokine receptors expressed on leukocytes, which are named according to 
their ligands (CC, CXC, CX3C), plus R for receptor. These receptors are seven 
transmembrane-spanning receptors that signal through coupled heterotrimeric G 
proteins. Chemokine receptor binding induces a signal transduction cascade that 
leads to activation of protein kinases and an increase in intracellular Ca2+ (Horuk 
2001). Within each subfamily, most chemokine receptors share multiple ligands 
(Cravens and Lipsky, 2002). Receptor expression is also a crucial determinant of 
the spectrum of action of chemokines. Leukocyte subpopulations (e.g., polarized 
Th1 and Th2 lymphocytes) or DCs at different stages of maturation show 
regulated receptor expression and responsiveness to chemokines. For example, 
expression of 'inflammatory' chemokine receptors, such as CCR2, CCR5, CCR6, 
CXCR1, and CXCR2 allows immature DC to respond to inflammatory 
chemokines produced at sites of inflammation by non-immune cells such as, for 
example, keratinocytes in the skin (Sallusto et al., 1999). Upon receiving 
appropriate chemokine stimuli, DC exits the tissues and enters the draining 
lymphatic vessel and move into the T-cell area of the lymph node. Migration of 
DC from the tissues into the lymphatics is accompanied by the down-regulation 
of chemokine receptors that bind inflammatory chemokines and an up-regulation 
of the chemokine receptor, CCR7, that binds to the chemokines, CCL21 
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expressed on the endothelial cells lining the lymphatic vessels and to CCL19 
expressed in the T cell areas of the lymphoid tissue (Förster et al., 1999; 
Robbiani et al., 2000).  
 Although our understanding of DC migration in response to inflammatory 
stimuli has grown, DC trafficking from normal tissues into the lymphatics in the 
absence of inflammation is less understood and it is likely that the mechanisms 
that regulate DC trafficking in a healthy individual will be disrupted in 
inflammatory diseases. 
 
 1.3. DC Maturation as a Control Point for Initiating Immunity 
 Immature DCs have phagocytic and endocytic function. For these purposes, 
they express different groups of receptor families on their surface, such as Fc 
receptors for antigen-antibody complexes, and pattern recognition receptors 
(PRR), such as the Toll like receptors (TLRs) and C-type lectin receptors (CLRs) 
that mediate endocytosis and, at the same time, enable DCs to recognize a wide 
range of microbial stimuli (Geijtenbeek et al., 2004).  
 Once DCs have captured antigens, they receive signals that induce further 
differentiation, called maturation. At this point, DCs form large vesicles to sample 
the foreign substances and then convert them into MHC-peptide complexes, 
while the cells migrate from peripheral sites to the T cell areas of the secondary 
lymphoid organs. The MHC class II–peptide complexes are then transported 
from the intracellular lysosomes to the cell surface. At the same time, DCs 
upregulate costimulatory molecules, such as CD80, CD86 and CD40. In addition, 
they increase MHC class I expression on their cell surface, and can activate a 
pathway called "cross-presentation" (Heath and Carbone, 2001). Through cross-
presentation, DCs can present nonreplicating exogenous antigens, e.g., from 
dying cells (Liu et al., 2002) (Luckashenak et al., 2008), noninfectious microbes, 
(Morón et al., 2003) and immune complexes (Regnault et al., 1999) to CD8+ 
cytotoxic T cells. Thus and although other cell types possess APC capacity, the 
ability of cross-presentation in context with the expression of costimulatory 
signals makes DCs superior in activating effector T cells. Other changes 
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occurring during the maturation process include production of proinflammatory 
cytokines by DCs and extension of their characteristic dendrites (Mellman and 
Steinman, 2001). 
 Finally the MHC-peptide complex expressed on the DC surface will be able 
to efficiently interact and activate naïve T cells expressing a specific T cell 
receptor (TCR). Strong adhesion between the cells is important for the crosstalk 
between DC and T cell, and is provided by integrin molecules that help form a 
dynamic structure described as “the immunological synapse”. Antigen recognition 
by the specific TCR leads to both clonal expansion and differentiation of CD4+ T 
cells, cytotoxic CD8+ T cells, or natural killer T cells that is targeted towards a 
specific pathogen. These ‘‘clonal expansion’’ phase occurs 7–10 days after the 
initiation of the immune response when the frequency of antigen specific T cell 
will markedly increase, as much as 100,000-fold, in the case of antigen-specific 
CD8+ T cells responding to viruses (Butz and Bevan, 1998; Murali-Krishna et al., 
1998). Importantly, some of these T cells will be used to immediately fight the 
infection while others will be maintained by the host as memory cells. The pool of 
memory cells can be quickly re-expanded to provide a strong response against 
future challenges by the same pathogen, affording long-lasting immunity. 
  In the absence of a microbial stimulus, immature dendritic cells can also 
present self-antigens to self-reactive T cells, which in turn get deleted or 
silenced, i.e. tolerized or expanded in the form of regulatory T cells. The nature of 
these tolerogenic DCs is still not clearly understood (Bonifaz et al., 2002). 
 The type of the maturation stimuli that tweak the DCs is also a critical 
aspect influencing the development of CD4+ T helper (Th)-cells into Th1 or Th2 
subsets or the activation of CD8+ Cytotoxic T cells or the class of antibodies 
secreted by B cells (Banchereau and Steinman, 1998; Iwasaki and Medzhitov, 
2004). Entry of a microbe into the body can also activate a range of other cell 
types, such as NK cells, NK T cells, basophils, mast cells, myeloid suppressor 
cells, tissue epithelial cells and stromal cells, all of which can influence DC 
function. Thus, DCs can sense microbes directly but also indirectly, through 
factors secreted by other immune cells and the microenvironment, and integrate 
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this information to orchestrate the immune response (Figure 1.1) (Pulendran et 
al., 2010). In this way, the type of response is adapted to the type of invading 
pathogen and the infected tissue.  
 Naïve CD4+ T cells are particularly plastic and can differentiate into several 
functional effector classes, including: 
- Th1 cells, which produce IFN-" and help the induction of CD8+ cytotoxic T cells 
(CTLs) are critical for the eradication of intracellular microorganisms such as 
Listeria monocytogenes bacteria and Leishmania major protozoa (Szabo et al., 
2003);  
- Th2 cells, producing interleukin-4 (IL-4), IL-5, IL-9, IL-13, and IL-25, are 
important for the elimination of extracellular parasites such as helminthes and 
nematodes (Pulendran et al., 2010); 
- Th17 cells, a more recently recognized pathway of helper T cell development, 
are abundant at mucosal interfaces, where they respond to infections with 
pathogenic bacteria and fungi. These cells produce mainly IL-17 and IL-22 
cytokines (Dong, 2008). 
Figure 1.1 Dendritic-cell control of pathogen-driven T-cell polarization 
(A) The classical view of how DCs polarize TH responses involves sensing microbial stimuli 
directly through various innate immune receptors expressed by DCs and the stimulation of 
distinct signaling pathways that mediate the production of different cytokines and factors that 
control TH polarization. (B) A revised view places the classical picture in the context of the cell-
cell interactions that occur (for example, basophils help TH2 polarization), together with 
conditioning from stromal cells and epithelial cells (Pulendran et al., 2008). 
 
 Besides effector cell lineages, CD4+ T cells can also differentiate into 
distinct regulatory lineages so-called T regulatory cells that suppress the 
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proliferation and differentiation of Th or cytotoxic T cells and serve to limit the 
potential immunopathology that might be caused by an overexuberant immune 
response. 
 A number of other factors can also influence the Th lineage commitment, 
including the type of activated DC presenting the antigenic peptide to the naïve T 
cell (Coquerelle and Moser, 2010). But first, the existence of different DC subsets 
needs to be introduced.  
 
2. DC subsets 
 In the recent years it has become clear that DCs do not represent one 
homogeneous population but rather form a plethora of distinct subsets that can 
be found in vivo. These DC subsets differ not only in phenotype, but also in their 
genetic program, are distributed in different microenvironments within the body 
and equipped to sense different types of pathogens and to modulate distinct 
classes of immune responses. 
 
 2.1. Classification criterion    
 Classification of the DC subsets can be difficult and opinions vary on which 
criteria is the best for categorization of the different sub-populations.  
 For example, the classification can be development oriented. For instance, 
DCs in the mouse lymphoid organs can require one of the two hematopoietins, 
the Fms-like tyrosine kinase ligand (Flt-3L) or the Granulocyte/Macrophage 
Colony Stimulating Factor (GM-CSF) for their development. This classification is 
an active current area of research.  
 In terms of lineage origins, DCs were once divided into myeloid or lymphoid 
DCs. This division was proposed in 1992 when it was found that T cell 
precursors, which are lymphoid committed cells, could form thymic DC (Vremec 
et al., 1992). The expression of markers that are normally expressed by 
lymphocytes (i.e., CD8!) was taken as a hint that these cells derived from 
lymphoid committed cells (Ardavin et al., 1993). In the meantime, it was also 
recognized that DCs could arise from myeloid precursors. Until now it is still not 
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clear what is the function of this cell marker on DCs. Nonetheless, the terms 
myeloid and lymphoid DC subsets are still used by some authors in relation to 
their expression of myeloid vs. lymphoid markers (CD11b vs. CD8!) but most 
feel that this type of distinction is not accurate in developmental terms. 
 Another type of nomenclature divides DCs according to whether they are 
“resident” or migratory. All DCs are generated in the bone marrow and migrate as 
precursor cells to sites of potential entry of pathogens. “Resident DCs” move 
directly to lymphoid tissue from a blood precursor, while “migratory DCs” first 
enter peripheral tissues (e.g. skin) before migrating through the lymphatics to the 
draining lymphoid organs.  
 An alternative classification distinguished plasmacytoid (PDC) from 
conventional DC (cDC) based on different morphology, surface markers, and as 
a result of more recent studies, gene-expression profiling that clearly put these 
two subsets apart (Robbins et al., 2008).   
 DCs can also be categorized on whether they are present in the uninfected 
steady state or whether they arise with infection or inflammation. 
 Any cell of the DC family, at any one time, should fit one of the classifiers 
described above. 
 
 2.2. Phenotype of mouse DCs subsets in peripheral lymphoid 
organs (Table 1) 
 Murine splenic DCs are certainly the most widely studied cells in DC 
biology. At steady state, splenic DCs constitutively express MHC class II and the 
integrin CD11c and can be subdivided into three major subsets: 
(i) CD11chigh CD8#+ CD11b- DEC205+ DCs [so called “CD8#+ DCs”]. This 
subpopulation corresponds to the original “lymphoid DC subset”. 
(ii) CD11chigh CD8#- CD11b+ DEC205- DCs [so called “CD8#- DCs”]. This subset 
can be further divided into two, based on the expression of CD4 or DCIR.  
(iii) CD11cintermediate CD8#+/- CD11b-DEC205- B220+ DCs [PDCs].  
Subsets (i) and (ii) correspond to the cDC for conventional or “classical” dendritic 
cells. 
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 In addition to these subsets we can find at least two additional 
subpopulations of DCs in the mouse lymph nodes, particularly the ones draining 
the skin, also called skin-draining lymph nodes (sdLNs): 
(i) CD11chigh CD8#low CD11b+ DEC205high Langerin+ [Langerhans cells (LCs)].  
(ii) CD11chigh CD8#- CD11b+ DEC205+ [dermal DCs]. This subset can be further 
sub-divided in two, based on the expression or not of the CD103 integrin. 
These two subsets found in the lymph nodes are commonly referred to as 
migratory DCs since, even in germ-free mice, they constantly travel from 
peripheral tissues (the epidermis or the dermis of the skin respectively), via the 
lymphatics, to the draining lymph node. In contrast, because the spleen lacks 
afferent lymphatic vessels, migratory DCs are distinctively absent from this 
organ.  
Table 1.1. Major DC subsets in the mouse lymphoid organs.  
Adapted from (Heath and Carbone, 2009) (Pulendran et al., 2008) 
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 The described DC subsets are found in the lymphoid organs under steady 
state conditions and represent just one aspect of the scope of the DC family. The 
complex DC system also includes many other intricacies associated with other 
non-lymphoid tissues such as the intestine and the lung where the different types 
of DCs are conditioned for important immune mechanism by the particular 
tissues, but that will not be explored in my thesis.  
 DC heterogeneity can be further extended to include monocyte-derived DCs 
generated under inflammatory conditions and that will be further discussed in this 
chapter. 
 DC subsets are currently well described on the basis of their surface 
phenotype. However, the origin and developmental relationship of these DC 
types is not yet entirely clear. In the next section, I will discuss some of proposed 
mechanisms concerning the origin and developmental relations existing between 
the different DC subsets in steady state or inflammatory conditions  
  
3. Origin of DCs in lymphoid tissues 
   
 3.1. In steady state conditions 
 Lymphoid and myeloid lineage divergence is an early step in 
haematopoiesis. Monocytes, macrophages, granulocytes, megakaryocytes, and 
erythrocytes differentiate from a common myeloid progenitor (CMP), whereas B, 
T, and natural killer (NK) cells differentiate from a common lymphoid progenitor 
(CLP) (Figure 1.2.). As with all other leukocytes, DCs also develop from bone 
marrow-derived hematopoietic stem cells. In the lymphoid tissues, DCs are in a 
dynamic balance, with an estimated half-life of only a few days during steady 
state conditions (Liu et al., 2007). Although this rapid turnover mandates a 
continuous replacement of DCs by a precursor population, the identities of 
hematogenous DC precursors that contribute to steady-state DC populations 
remain a subject of controversy, and attempts to identify committed DC 
precursors have led to a range of results that I will summarize in the next 
paragraphs. 
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Figure 1.2 Hematopoietic tree for dendritic cell development. 
Hematopoiesis is initiated in bone marrow multipotent hematopoietic stem cells. Further 
downstream, lineage differentiation potential branches into progenitors committed to myeloid 
cells, common myeloid progenitors (CMPs), or lymphoid cells, common lymphoid progenitors 
(CLPs). CMPs then further differentiate to megakaryocyte/erythrocyte progenitors (MEPs) and 
granulocyte/macrophage progenitors (GMPs). Alternatively, CMPs can develop into macrophage-
DC progenitors (MDPs) that give rise to monocytes, macrophages, classical DCs (cDCs), and 
plasmacytoid DCs (pDCs). MDPs-derived monocytes can further differentiate into inflammatory 
DCs. MDPs lie upstream of the common DC progenitors (CDPs), which are DC-restricted, giving 
rise to pDCs and, via pre-DCs, to cDCs. Solid arrows show demonstrated pathways; dotted 
arrows show suggested pathways that have not been formally proven (Schmid et al., 2010). 
 
 The differentiation of hematopoietic stem cells requires the integration of 
environmental signals surrounding the cell. In their microenvironments, 
hematopoietic progenitors interact via receptors with ligands present in the 
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extracellular matrix. In these developmental niches, cytokines can act locally as 
secreted factors or in membrane-bound forms in direct cell-to-cell contacts. In 
addition, cytokines can act distantly from where they were produced by travelling 
along the bloodstream or lymph vessels (Kondo et al., 2003).  
 To maintain homeostasis in the DC compartment, two major players are 
involved, the GM-CSF and the Flt3L, that were previously mentioned in the 
context of DC classification criterion. The macrophage–colony stimulating factor 
(M-CSF) is also involved and controls the segregation of monocytes into fully 
differentiated macrophages. These are all growth factors know to be potent 
stimulators of hematopoietic progenitor cell expansion and mobilization 
(Robinson et al., 2000) (Figure 1.3). 
 The use of genetically deficient mice has shaped our current view on the 
identity of cell progenitors and the cytokine requirements for the development of 
different DC subsets. For example, GM-CSF-deficient mice or mice lacking the 
GM-CSF receptor common ! chain have only minor decreases in splenic cDCs 
compared with wildtype mice and a maximal threefold reduction in lymph node 
cDCs. In addition, transgenic mice overexpressing GM-CSF showed only a small 
increase in cDCs (Vremec et al., 1997), whereas monocytes are missing in mice 
lacking M-CSF receptor (c-fms or CD115) (Dai et al., 2002; Ginhoux et al., 2006). 
On the other hand, mice with a targeted gene deletion of Flt3L or Flt3 (the Flt3L 
receptor also known as CD135 or Flk2) have severely reduced numbers of cDCs 
and PDCs (D'Amico and Wu, 2003; Geissmann et al., 2010; Ginhoux et al., 2006; 
Maraskovsky et al., 2000; Waskow et al., 2008). Consistent with these 
observations, Flt3L injection induces selective expansion of cDCs, PDCs and 
myeloid cells but not B or T lymphocytes (Maraskovsky et al., 1996). Thus, the 
data suggest that most DCs found in the lymphoid organs in steady state are 
independent of monocytes. The exception seems to occur with DCs in peripheral 
organs like lung and intestine that do appear to arise from monocytes on an 
ongoing basis (Varol et al., 2007), raising the interesting possibility that the origin 
of DCs in non-lymphoid tissues is different from spleen and lymph nodes. In this 
thesis I will however concentrate on the mechanisms that determine DC 
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development from monocytes in the lymphoid tissues. 
Figure 1.3. Model for cytokine-induced differentiation of DCs  
MDPs and CDPs commitment is dependent on cytokine exposure. These two cell percursors 
express the receptors for Flt3L (green), GM-CSF (red), and M-CSF (yellow). MDPs have the 
potential to differentiate into macrophages, monocytes, and inflammatory DCs, and via CDPs to 
cDCs and PDCs. Different microenvironments with variations in the combination and 
concentration of the three cytokines influence the lineage commitment and differentiation of 
MDPs and CDPs into mature cells (Schmid et al., 2010). 
 
 The initial reports regarding the origin of DCs were the studies of Inaba et 
al. reporting that granulocytes, macrophages and DCs could arise from a yet 
unknown MHC class-II-negative common progenitor cell during in vitro cultures of 
mouse bone marrow cells. In this setting, the development of monocytes into 
DCs (called monocyte-derived DCs [Mo-DCs]) required the presence of the GM-
CSF in the cultures (Inaba et al., 1993). Sallusto and Lanzavecchia, and Romani 
further proved this notion in a report indicating that human DCs can be 
differentiated in vitro from blood monocytes (Sallusto and Lanzavecchia, 1994) 
(Romani et al., 1994).  
 In contrast with a simplistic view of lineage development, a pioneer study by 
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Traver et al. in 2000, showed that the DC potential is maintained along the two 
early branches of the hematopoietic system and both CMP or CLP could give 
rise to spleenic cDCs (Traver et al., 2000) (Figure 1.2).  Therefore, the terms 
“lymphoid” and “myeloid” are not longer used in the context of DC development. 
In this same study, MDPs were identified. The name stands for Macrophage and 
DC progenitor, because of the potential to develop into DC or Macrophages 
depending on the microenvironment encountered at tissue sites e.g. cytokine 
signals (Traver et al., 2000) (Figure 1.2. and Figure 1.3.). Phenotypically, MDPs 
are defined by the absence of markers for lineage-committed precursors such as 
CD3 (a T cell marker), CD19 (a B cell marker) and CD11b (a marker of 
monocytes in the BM), but express both the CD117 (c-kit, the receptor for stem 
cell factor) or the chemokine receptor Cx3CR1. MDPs were shown to give rise to 
monocytes, to several subsets of macrophages, and to steady state splenic 
CD11c+CD8#+ and CD11c+CD8#- DCs (cDCs) in vivo. In contrast, the MDP is 
devoid of lymphoid, erythroid, and megakaryocytic potential, also lacking 
polymorphonuclear leukocytes differentiation potential and therefore do not give 
rise to any granulocytes including eosinophils, basophils and neutrophils (Traver 
et al., 2000) (Figure 1.2). 
 Some years later, Onai et al, identified the CDPs for common DC precursor, 
in the mouse bone marrow. CDPs give rise exclusively to cDCs and pDCs, but 
not to other cell lineages, both in vitro and in vivo. Phenotypically, CDPs lack 
specific lineage markers and are negative for CD11c and MHC-II. On the other 
hand, they express the receptor for the Flt3L (CD135), the receptor for M-CSF 
(CD115) and the receptor for stem cell factor (c-Kit) (Onai et al., 2007).  With this 
study, the divergence between the monocyte and the DC lineages was found to 
occur in the bone marrow and between the MDP and the CDP stages of 
development (Figure 1.2). Thus, lymphoid tissue cDCs, PDCs, and monocytes 
share a common progenitor, the MDP, whereas the CDP is restricted to produce 
cDCs and PDCs under steady state conditions.  
 A more recent study by Liu et al, defined the point of divergence between 
multipotential CDP precursors and cDC-restricted progenitors in the bone 
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marrow. Taking advantage of the persistent expression of CD135 throughout pre-
DCs development, it was shown that CDPs move into the blood to seed both 
lymphoid and non-lymphoid tissues forming CD11chi, MHC IIhi DCs (Liu et al., 
2009).  
 
        3.2. Under inflammatory conditions 
 As previously denoted, monocytes can also develop many of the phenotypic 
features of DCs but they are not, in contrast with CDPs, precursors for lymphoid 
organ DCs in the steady state.  
 The question of how DCs can arise from monocyte precursors has proven 
to be a vexing issue and will be explored in more detail in the next paragraphs. 
 Monocytes are circulating cells of the mononuclear phagocyte system that 
were first studied as macrophage precursors, mainly in vitro (Johnson et al., 
1977) (de Villiers et al., 1994). Monocytes were later recognized to have an 
added potential to develop into DCs and this facet was primarily suggested from 
the in vitro studies with mouse bone marrow monocytes or using human blood 
monocytes, as previously cited (Inaba et al., 1993) (Sallusto and Lanzavecchia, 
1994) (Romani et al., 1994). These in vitro fully differentiated Mo-DCs acquire a 
typical dendritic cell probing morphology, while losing the capacity to 
phagocytose and to adhere to various tissue culture surfaces. At the same time, 
in vitro derived Mo-DCs acquire strong capacities to initiate immunity including 
enhanced capacity for antigen presentation and T cell stimulation. Hereof, Mo-
DCs can immunize humans (Dhodapkar et al., 1999) (Schuler-Thurner et al., 
2000) and home to the T cell areas of lymph nodes (LNs) (de Vries et al., 2003). 
In addition, monocytes are almost 20 times more abundant than DCs in blood 
and bone marrow, so the mobilization of this cell reservoir in vivo in order to 
generate potent antigen-presenting DCs has an important therapeutic potential 
but is not fully understood.  
 The first description of the differentiation of mouse monocytes into DCs in 
vivo was reported in 1999 by Gwendalyn Randolph using an experimental model 
based on the subcutaneous injection of fluorescently labeled latex microspheres 
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with the purpose of inducing a local dermal inflammation to which monocytes 
could be recruited and allowing the tracking of the cells that had internalized 
them. Data from this study allowed for the conclusion that monocytes recruited to 
the inflamed dermis differentiated locally into macrophages, as well as DCs that 
subsequently migrated to the draining lymph nodes (Randolph et al., 1999). In 
line with these findings, but using a different experimental model that promotes 
the exit of Langerhans cells from the inflamed skin after exposure to UV, the 
group of Miriam Merad has established that monocytes recruited to the skin 
could differentiated into epidermal Langerhans cells and that this process was 
dependent on M-CSF (Ginhoux et al., 2006). However, in steady state 
conditions, epidermal langerhans cells derive from local non-monocytic 
precursors (Merad et al., 2002).  
 More recent reports, have also reveled that monocytes could be precursors 
of some DC subsets found in the lung and intestinal laminal propria under steady 
state conditions, but majors efforts has been taken in order to identify the role 
played by Mo-DCs during the immune response against clinically relevant 
pathogens. In this regard, several reports have begun to document in mice the 
differentiation of CD11c# and MHC II# blood monocytes into large numbers of 
CD11c+ MHC II+ Mo-DCs during different infection models, e.g., Leishmania 
major infection via the skin (León et al., 2007), intravenous infection with Listeria 
monocytogenes (Serbina et al., 2003), influenza virus infection via the airway 
(Nakano et al., 2009), Aspergillus fumigatus in the lung (Hohl et al., 2009), T cell-
mediated colitis (Siddiqui et al., 2010), and injection of the adjuvant, alum (Kool 
et al., 2008). Although these studies support the view that monocytes could 
behave as DC precursors after recruitment to the inflammatory foci related to 
each one of these pathological conditions, research on Mo-DCs have been 
limited by the lack of specific markers to localize them in vivo. and to isolate 
them, in order to look for features that characterize dendritic cells such as their 
morphology, their location into the T cell areas, and their capacity to capture 
antigens for cross presentation on MHC I. 
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 In summary, there is a certain type of flexibility in terms of DC subtype 
production, at the level of the early hemopoietic precursors. The points 
downstream of these precursors where the DC sublineages diverge and become 
more fixed, and the factors determining this divergence, need to be elucidated. 
However, different functions have been attributed to the different DC subsets. 
Some of these functional differences will be further discussed. 
  
4. Different DC subsets are involved in different types of immune 
responses.  
 Classically, knowledge on DC biology was concentrated on their capacity to 
initiate immune responses following encounter with different maturation stimuli. 
The field has expanded considerably with the studies showing the existence of 
different DC subsets expressing different receptors for antigen uptake and thus 
involved in different immune mechanisms. Therefore, for each DC subset 
previously described, specialized immune functions have been recognized.  This 
specific DC-subset function has been also shown to correlated with the profile of 
pattern recognition receptors (PRR) expression, such as Toll Like Receptors and 
C-Type lectins, with the type of cytokines that each subset secrets, and with the 
microenvironmental location of a certain DC subtype within the lymphoid organs 
(Figure 1.1 and Table 1) 
 For example, CD11chigh CD8#+ DCs express high amounts of messenger 
RNA for TLR3 but do not express TLR7 and may be therefore specialized for the 
recognition of double stranded RNA viruses, known agonists for TLR3 (Edwards 
et al., 2003) (Schulz et al., 2005). More recent proteomics data also revealed the 
specific expression of TLR12 and TLR13 on CD8!+ DCs (Luber et al., 2010). 
This particular subset of DC localize in the T-cell rich areas of the spleen and 
lymph nodes (Vremec et al., 2000) and upon TLR activation secrete large 
amounts of IL-12 (p70) (Reis e Sousa et al., 1997). This cytokine is important for 
the formation of CD4+ Th1 cells (Maldonado-López et al., 1999) and cytotoxic 
CD8+ T cell priming (Felzmann et al., 2005). By contrast, CD8#- DCs do express 
TLR7 and are particularly enriched for other families of cytoplasmic nucleic acid 
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receptors, the RIG-I-like helicases RIG-I and MDA-5, important in the recognition 
of single stranded RNA viruses (Luber et al., 2010).  CD8#- DC are localized in 
the red pulp and marginal zone of the spleen (Dudziak et al., 2007) where they 
can be marked using the 33D1 anti-DCIR2 antibody. But the study of this 
population in the lymph nodes has been limited by the lack of specific markers for 
staining. CD8#- DCs are a major source of IL-10 and IL-4 and have been shown 
to induce Th2 responses (Maldonado-López et al., 1999; Maldonado-López et 
al., 2001).  
  Another important subset in the DC biology, the PDCs are able to produce 
large amounts of type I interferons upon exposure to both live and inactivated 
viruses. This is because PDCs express Toll-like receptor 7 (TLR7) and TLR9 in 
the endossomes (Villadangos and Young, 2008). 
 With regard to cross-presentation of particulate or soluble protein antigens 
to CD8+ T cells, the CD8#+ DCs are more efficient comparing with the other DC 
subsets (den Haan et al., 2000) (Pooley et al., 2001). Furthermore, CD8#+ DCs 
are preferentially able to endocytose dying cells in vivo and present cell-
associated antigens to both CD4 and CD8 T cells (Iyoda et al., 2002). The CD8#- 
DCs are, in contrast, more efficient for presentation of antigens for the MHC-II 
pathway, irrespective of activation status or mode of Ag acquisition (Kamphorst 
et al., 2010) and this is consistent with the differential antigen-processing ability 
of CD8#+ versus CD8#- DC subsets (Dudziak et al., 2007). In contrast, activated 
PDCs express lower levels of CD11c, MHC class II and other T-cell costimulatory 
molecules and are therefore much less efficient at T-cell priming comparing with 
the other DC subsets (Villadangos and Young, 2008).  
 The other two additional subsets found in the lymph nodes, the Langerhans 
cells and the dermal DCs (or migratory DCs) are found in the periphery (e.g. 
skin) in an immature state. However, by the time they reach the draining lymph 
node, they are found in a mature state expressing high levels of MHCII and 
costimulatory molecules (Jakubzick et al., 2008; Wilson et al., 2003). In terms of 
T cell priming capacities, a recent study has shown that CD103+ dermal DCs 
were the migratory subset most efficient in the presentation of antigens of herpes 
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simplex virus type 1 to naive CD8+ T cells, but were comparable to all other DC 
subsets in the draining lymph node for presentation of these antigens to CD4+ T 
cells (Bedoui et al., 2009).  
 In order to find additional molecular differences between DC subsets, 
several genomic approaches have been taken. This led to the identification of a 
series of genes that encode lectin-like receptors, some of which are remarkably 
DC specific. These lectins are members of the C-type lectin receptor family 
(CLRs) and will be subject of detailed description in the next section.  
 
5. C-type lectins on DCs are key modulators of the immune 
responses 
 The term C-type lectin was introduced to distinguish between Ca2+-
dependent and Ca2+-independent carbohydrate-binding lectins. CLRs share at 
least one carbohydrate recognition domain (CRD), which is a compact structural 
module that contains conserved residue motifs and determines the carbohydrate 
specificity of the CLR (Zelensky and Gready, 2005). CLRs exist both as soluble 
and transmembrane proteins, but for the purpose of my thesis I will only discuss 
the transmembrane CLRs that function as PRRs.  
 As previously noted, immature DCs express an abundant variety of PRRs to 
interact with a broad spectrum of invading pathogens. The most abundant PRRs 
expressed on DCs include the archetypical TLRs, and CLRs. In contrast to TLRs, 
CLRs can recognize carbohydrate structures on pathogens. Thus, CLRs are 
particularly important for internalization of glycosylated antigens into intracellular 
compartments present on DCs enhancing presentation of the antigens on MHC I 
and II, without inducing DC maturation (Figdor et al., 2002). For this reason, 
CLRs are also called endocytic receptors or antigen-uptake receptors, and some 
of them do not have any known innate signaling function other than endocytosis.  
 Although TLRs and CLRs recognize different determinants and have 
distinct functions, various studies suggest that CLRs may also modulate immune 
reactions through cross-talk with other receptors and especially with TLRs. This 
indicates that the outcome of an immune response is determined by the balance 
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between triggering of the two receptor families (Lee and Kim, 2007). 
 So far more than 15 CLRs have been identified on DCs and macrophages.  
These CLRs can be divided into two groups depending on the orientation of their 
amino (N) terminus (Figure 1.4.) (Figdor et al., 2002). 
Group I – the N-terminus is pointing outwards from the cytoplasm of the cell, and 
include the Macrophage Mannose Receptor (MMR or CD206) and the DEC-205 
(CD205). Lectins of this group contain several CRDs. 
Group II - the N-terminus is pointing into the cytoplasm of the cell. Include, the 
Dendritic Cell-Specific Intercellular adhesion molecule 3-Grabbing Nonintegrin 
(DC-SIGN or CD209), the DC-associated C-type lectin 1 (Dectin-1; also known 
as CLEC7A) and DC immunoreceptor (DCIR; also known as CLEC4A). The type 
II surface lectins produced by DCs contain a single CRDs domain. 
 Depending on the amino acid sequence, the CRD bears specificity for 
mannose, galactose, or fucose structures. However, binding of these 
carbohydrate structures to the different CLRs is also dependent on carbohydrate 
branching, spacing, and multivalency (Zelensky and Gready, 2005). 
 
 5.1. C-type lectins receptors are differentially expressed on 
different DC subsets 
 CLRs are differentially expressed by various subsets of DCs. For 
example, DEC-205 (CD205) is most abundant on CD8#+ DCs . In contrast, the 
DCIR2 is a marker for the CD8#- DCs subset especially in the spleen. MMR and 
DC-SIGN are hallmarks of in vitro cultured monocyte derived DCs, while 
Langerin (CD207) expression is restricted to epidermal Langerhans cells and 
dermal DCs found in the skin and migrating to the skin draining lymph nodes.  
The CLR CLEC9A is expressed at high levels by the murine and human CD8#+ 
DCs (Geijtenbeek and Gringhuis, 2009).  
 A broad set of mAb against particular CLRs is currently available and used 
to study specific DC-subsets.  In addition, it is becoming clear that these 
differences in expression reflect differences in antigen capture, developmental 
pathways and migration patterns attributed to each DC-subset. 
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Figure 1.4. C-type lectins expressed by dendritic cells 
Type I C-type lectins includes MMR and DEC-205, contain an amino-terminal cysteine-rich repeat 
(S–S), a fibronectin type II repeat and 8–10 carbohydrate recognition domains (CRDs), which 
bind different ligands in a Ca2+-dependent manner.  
Type II C-type lectins contain only one CRD at their carboxy-terminal extracellular domain.  
The cytoplasmic domains of the C-type lectins are diverse and contain several conserved motifs 
that are important for antigen uptake. Some type II C-type lectins contain potential signaling 
motifs like ITIM, ITAM, proline-rich regions (P). CLEC-1, C-type lectin receptor 1; DCIR, dendritic 
cell immunoreceptor; DC-SIGN, dendritic-cell specific ICAM-3 grabbing non-integrin; DLEC, 
dendritic cell lectin; ITAM, immunoreceptor tyrosine-based activation motif; ITIM, immunoreceptor 
tyrosine-based inhibitory motif; MMR, macrophage mannose receptor (Figdor, 2002). 
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 5.2. Therapeutic potential of C-Type lectins 
 As discussed above, signaling via CLR can induce specific immune 
responses.  This is because CLR-mediated signaling can control intracellular 
routing of antigen. Thus, depending on the CLR targeted, either CD4+ or CD8+ 
T-cell responses can be specifically induced.  
A promising vaccination strategy that has been exploited in our laboratory 
relies on the in vivo targeting of specific receptors by antibodies coupled to 
antigens. This strategy allows specific and efficient delivery of antigens to DCs. 
(Tacken et al., 2007). Because of their restrictive expression by DC subsets and 
their function as uptake receptors CLRs have been prime candidates for this in 
vivo targeting vaccination strategy. For example, using our targeting strategy to 
different CLRs, known to be specifically expressed on CD8#+ DCs, such as 
DEC-205, Langerin or Clec9A, induces comparable antigen-specific CD4+ and 
CD8+ T cell responses (Idoyaga et al., 2011). It was also shown in other studies 
that targeting of DEC205 by antibodies in the absence of an adjuvant such as 
CD40 or TLR ligands did not result in DC maturation but induced tolerance 
(Bonifaz et al., 2002). These results proved that targeting of DEC205 with an 
antibody without further maturation does not result in immune activation, which is 
a pivotal requirement for the induction of tolerance. It also suggests that DEC205 
does not induce signaling after antibody cross-linking. Identification of the DEC-
205 natural ligands will reveal whether this receptor induces or modulates 
immune responses after ligand triggering. 
 In the overall, these studies suggest that signaling through some CLRs can 
be used to redirect immune responses. A better understanding of the different 
CLRs and pathways involved might provide new targets for modulating immune 
responses. This knowledge may further tailor vaccine design.  
 
 
 
 
 
! %,!
6. The DC-SIGN Receptor 
 The Dendritic Cell-Specific Intercellular adhesion molecule 3-Grabbing 
Nonintegrin (DC-SIGN) also known as CD209 was originally described in 1992 
as a human placental protein capable of binding to human immunodeficiency 
virus type 1 (HIV-1) gp120 envelop glycoprotein with high affinity (Curtis et al., 
1992). It was subsequently shown to be highly expressed on dendritic cells (DCs) 
and to bind to the intercellular adhesion molecule (ICAM)-3 on resting T cells, 
thus participating in DC-mediated activation of naive T-lymphocytes (Geijtenbeek 
et al., 2000c). These two pioneering studies prompted the investigation of several 
aspects of the DC-SIGN receptor. 
 
 6.1. Structure of DC-SIGN  
 As most C-type lectins, DC-SIGN is a type II transmembrane protein 
containing one carbohydrate recognition domain (CRD) (Figure 1.5). The CRD of 
DC-SIGN is a globular structure containing two Ca2+ binding sites important for 
the conformation and the coordination of carbohydrate ligands (Feinberg et al., 
2001; Geijtenbeek et al., 2002). The CRD is then separated from the 
transmembrane region (TM) by a neck domain, which is composed of seven and 
a half tandem repeats, followed by a cytoplasmic tail containing recycling and 
internalization motifs, such as a di-leucine (LL) motif and the tri-acidic (EEE) 
clusters (Engering et al., 2002). Binding of ligands to the DC-SIGN receptor leads 
to conformational changes that increase the binding affinity of ligands containing 
repetitive sugar moieties. This conformation changes (tetramerization) occur 
through the DC-SIGN neck-repeat domain (Figure 1.5B).  The hydrophobic necks 
are believed to stabilize the DC-SIGN oligomers and project the CRDs away from 
the cell surface, which positions the receptor for appropriate multivalent 
interaction with glycan ligands (Svajger et al., 2010).  
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Figure 1.5. Different representations of the structure of DC-SIGN.  
A. Linear representation, DC-SIGN is a type II trans-membrane C-type lectin that consists in the 
extracellular N-terminus domain containing the C-type lectin domain and the neck region, 
represented in green and blue, respectively. The intracellular C-terminus contains the 
transmembrane domain (brown) and a cytoplasmatic tail (red). The cytoplasmatic tail includes 
internalization motifs, such as the dileucine motif (LL), the tri-acidic cluster (EEE) and an 
incomplete immunoreceptor tyrosine-based activation motif (Y). B. A ribbon diagram of the C-type 
lectin domain of DC-SIGN. The two #-helices are shown in blue, the !-strands in red, the calcium 
ions in green, and the three disulphide bridges in yellow. Both the N- and the C-termini are at the 
bottom of the image. The structure was determined by molecular modeling. C. DC-SIGN 
tetramer. The tetramerization occurs through hydrophobic residues stacking in the neck-repeat 
domain represented in blue. Adapted from (Geijtenbeek and van Kooyk, 2003) (Wu and 
KewalRamani, 2006). 
 
 The structure of DC-SIGN indicates that the CRD can bind to distinct 
carbohydrate moieties, but it seems to be selective to mannose- and fucose-
containing oligosaccharide patterns found in the envelopes of many viruses (e.g. 
HIV, Cytomegalovirus, Dengue, Ebola, Herpes simplex virus, coronaviruses, 
H5N1, West Nile virus, measles virus) and the membranes of non-viral 
pathogens such as bacteria (Helicobacter pylori, Mycobacterium tuberculosis, 
Klebsiella pneumonae and Leptospira interrogans), fungi (Candida albicans and 
Aspergillus fumigatus) and intracellular parasites (Leishmania, and Schistosoma 
mansoni) (van Kooyk and Geijtenbeek, 2003). In particular for HIV-1 (Snyder et 
al., 2005) and Ebola virus (Marzi et al., 2006), it has been shown that differential 
glycosylation (post-translational modification mediated by the expression of 
different enzymes which add or remove specific carbohydrate residues) of the 
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envelope glycoproteins affects binding of DC-SIGN and subsequently alter 
ligand-receptor interactions. 
 DC-SIGN can also recognize self glycoproteins such as the intercellular 
adhesion molecule 2 (ICAM2) and ICAM3, and functions as a cell-adhesion 
receptor that regulates DC migration and DC-T cell interactions, respectively. 
These functions will be explained in more detail in the next sections. 
 DC-SIGN ligation to the different carbohydrate structures can result in 
transmission of intracellular signaling. This signaling pathway is not yet fully 
understood but it has been associated with the presence of the di-leucine motif 
and a tyrosine residue in the cytoplasmic tail of the DC-SIGN oligomer (Hodges 
et al., 2007). It is however described how DC-SIGN activation can also modulate 
TLR signaling (TLR3, TLR4 and TLR5) through RAF1-dependent acetylation of 
the nuclear transcription factor NF-kB (Gringhuis et al., 2007).  
 
 6.2. Expression of DC-SIGN 
 In humans, DC-SIGN has been reported to be expressed in subpopulations 
of DCs and macrophages in the dermis of the skin, the T cell areas of tonsils, 
lymph nodes and spleen and in the lamina propria of mucosal tissues such as 
rectum, uterus, colon, vagina, cervix and lungs (Ebner et al., 2004; Geijtenbeek 
et al., 2000c; Granelli-Piperno et al., 2005; Jameson et al., 2002; Pack et al., 
2008; Soilleux and Coleman, 2001; Soilleux et al., 2002). Particularly, in the 
lymph nodes, the majority of DC-SIGN+ DCs are located near the entry points for 
lymph in the cortical sinuses. In contrast, most DCs in the paracortex fail to 
express DC-SIGN (Soilleux, 2003). The receptor is not expressed on Langerhans 
cells and PDCs Geijtenbeek, 2000 #1386} (Jameson et al., 2002; Soilleux and 
Coleman, 2001) but is a very well reported marker of fully differentiated human 
monocyte derived DCs generated in vitro with GM-CSF and IL-4 from CD14+ 
blood monocytes. The expression of DC-SIGN is, in this setting, dependent on 
IL-4 signaling (Relloso et al., 2002).  
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In humans, there is gene homologue for DC-SIGN called DC-SIGNR or L-SIGN 
(Soilleux et al., 2000). In contrast with DC-SIGN, DC-SIGNR is expressed  
on microvascular endothelial cells, especially in the liver sinusoids and lymph 
nodes (Pöhlmann et al., 2001). The two DC-SIGN genes, together with CD23 
(low affinity receptor for IgE or Fc$RII) and the CLEC4G, are all located next to 
each other on the same chromosome locus, forming a cluster of genes that is 
conserved across different mammalian species (Figure 1.6). 
 
Figure 1.6. Syntenic regions of mouse chromosome 8 and human 
chromosome 19 showing the position of the DC-SIGN/CD209 (in red) next 
to the Clec4G and CD23 genes. 
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 Five mouse homologues of human CD209 were described (Caminschi et al., 
2001; Park et al., 2001). These mouse homologues have 65 to 70% sequence 
similarity with human CD209 in the carbohydrate recognition domain (CRD) and 
have diverged from one another substantially on the basis of sequence similarity.  
However only one of the five mouse homologues, named mouse DC-SIGN, is 
expressed in spleen, in contrast with the other four, named SIGN-Related genes 
(SIGNRs), which are not.  
 Like human DC-SIGN, the mouse gene is located adjacent to the CD23 
gene, whilst the other four SIGNR genes are located close to each other in a 
neighboring region of the chromosome 8 (Park et al., 2001) (Figure 1.7). 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7. Illustration of chromosomal location and genomic organization 
of mouse DC-SIGN homologues and adjacent genes on chromosome 8 
A1.2–1.3.  
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 Unlike the human DC-SIGN, which is one of the most studied C-type 
lectins, neither the expression nor the function of mouse DC-SIGN protein has 
been examined in detail because of a lack of good antibodies. The two mAbs 
available against mouse DC-SIGN, clone 5H10 (Caminschi et al., 2006) and 
clone LWC06 (eBioscience, San Diego, CA) are unable to detect DC-SIGN in 
mouse tissue sections. On the other hand, studies in humans are limited and do 
not address function and developmental mechanism of DC-SIGN+ cells in vivo.  
 
 6.3. Immunological functions of DC-SIGN 
 Besides its function in self and non-self carbohydrate recognition, DC-SIGN 
has been proposed to play a role in 3 different aspects of the immune response 
controlled by DC: 
1) Migration – As mention previously, the capacity to migrate allows DCs to exert 
a continuous surveillance for incoming foreign antigens and a prompt response 
to present them to T cells. In this regard, DC-SIGN behaves as a DC-specific 
rolling receptor binding to the adhesion molecule ICAM-2, that is constitutively 
expressed on the endothelium of both blood and lymphatic vessels, as well as on 
high endothelial vascular cells. In this way, the egress of precursor DC from 
blood into tissues is mediated by DC-SIGN-ICAM-2 interactions that facilitate 
both rolling and trans-endothelial migration of DC-SIGN+ cells (Geijtenbeek et al., 
2000a). 
2) T cell priming – Because of the strong binding with ICAM-3 on resting T cells, 
initial studies suggested that DC-SIGN was required for the formation of the 
immunological synapse. Later, with the demonstration that ICAM-3 is recruited to 
the contact region of APCs (B cells were used) with T cells the notion that DC-
SIGN participates in DC-T cell clustering formation was reinforced (Montoya et 
al., 2002). However, more recent studies showed that blocking of DC-SIGN 
receptor has no effect on the proliferation capacity of T cells on MLR assays 
(Granelli-Piperno et al., 2005). Therefore, the requirement of DC-SIGN on DC to 
prime T cell proliferation has remained controversial.                                                               
3) Antigen capture and presentation – Binding of soluble ligands to DC-SIGN 
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induces rapid internalization from the cell surface, mediated by the dileucine-
motif present on the cytoplasmic domain of the receptor (Engering et al., 2002). 
Additionally, the tri-acidic cluster is important for targeting to late endosomal or 
lysosomal compartments where DC-SIGN ligands are processed for MHC class 
II presentation to T cells (Azad et al., 2008) (Geijtenbeek and van Kooyk, 2003). 
Thus, DC-SIGN can also function as an endocytic receptor for pathogenic 
antigens just like other C-type lectins. 
 
C. Aims of the project 
 While there is a good deal of research on human Mo-DCs from in vitro 
cultures, the different fates of monocytes in vivo under inflammatory conditions 
remains a matter of discussion. In this regard, previous studies have used a 
combination of CD11b and CD11c markers to help identify inflammatory 
monocytes with some features of DCs (Kool et al., 2008; León et al., 2007; 
Nakano et al., 2009; Serbina et al., 2003) (Hohl et al., 2009; Siddiqui et al., 
2010). However, these integrins are not sufficient to permit localization in situ, 
and given the heterogeneity and functional specialization of DCs, they are 
inadequate to define a specific subset. Previous isolations also used antibodies 
to Ly6C or Gr-1, but these markers are known to be lost during in vitro 
development of bone marrow monocytes into DCs (de Bruijn et al., 1994; 
Osterholzer et al., 2009; Sunderkötter et al., 2004). In addition, the correlation of 
DC-SIGN expression in human Mo-DCs and the equivalent cells in the murine 
system has never been accessed due to the lack of sensitive antibodies able to 
recognize the mouse receptor. 
 To address these gaps, we aimed to produce new mAbs to the mouse DC-
SIGN/CD209a to label Mo-DCs in cell suspensions and tissue sections. Using an 
in vivo labeling approach to isolate DC-SIGN-expressing cells from lymph nodes, 
we studied the function of Mo-DCs and we define a new pathway of 
differentiation in which monocytes are recruited to the lymph nodes in response 
to infection by gram-negative bacteria where they rapidly become DCs with the 
potential to present antigens to T cells. 
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Chapter 2. Experimental Procedures 
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2.1. Cell lines, mAbs production and labelling 
 MMD3 or IgG2c isotype control hybridomas and Chinese hamster ovary 
(CHO) cell lines were cultured in DMEM (GIBCO Invitrogen) with 5% FBS 
(Sigma) or 5% Ultra-Low IgG FBS (GIBCO Invitrogen) respectively. The medium 
was supplemented with 1x solutions of Antibiotic-Antimycotic (GIBCO Invitrogen), 
Non-Essential Amino Acids (GIBCO Invitrogen) and 0.1% of 2-!-
Mercaptoethanol (GIBCO Invitrogen). Hybridoma cells were expanded using 490 
cm2 roller bottles for 10-15 days. The cultured cells were centrifuged and filtrated 
to remove dead cell debris, and the supernatants were passed through protein G 
beads (Pierce). The purified mAbs were labeled with Alexa 647 (Molecular 
probes, Invitrogen) or EZ-Link Biotin (Pierce) reagents following the 
manufacture’s instructions. Produced mAbs were tested for endotoxin 
contamination (QCL-1000 kit, BioWhittaker). 
 
2.2. Animals   
 DC-SIGN knockout mice were generously provided by the Consortium for 
Functional Glycomics (Scripps Res. Inst., La Jolla, CA). Flt3-/- (I. R. Lemischka, 
Mount Sinai School of Medicine), MyD88-/- (S. Akira, Univ. of Osaka) and MyD88-
/-Trif-/- (E. Pamer, Memorial Sloan-Kettering Cancer Center) were provided by M. 
Nussenzweig (Rockefeller Univ.) and iDTR mice by A. Waisman (Univ. of Mainz). 
C57BL/6J (CD45.1 or CD45.2), C3H/HeJ, chemokine receptor (CCR2, CCR5, 
CCR6, and CCR7) knockouts, Lysozyme-M Cre (LysMCre), and CD14 KO mice 
were obtained from Jackson. F1, C3H/HeN and splenectomized mice were 
obtained from Taconic Farms. All animals were maintained under specific 
pathogen-free conditions and use at 6-10 wks old, females or males, according 
to institutional guidelines of the Rockefeller University. 
 
2.3. Antibodies  
 All fluorochrome-labeled mAbs are listed in Table 2 and were purchased 
from BD Biosciences, eBiosciences or Biolegend. We purchased anti-mouse IgG 
isotypes with HRP or PE from Southern Biotech (Birmingham, AL) that were 
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used for Western blot and CHO-binding assays, respectively. Other reagents 
were Live/Dead Fixable Aqua (Invitrogen) or DAPI (Sigma) as dead cell markers.  
Antibody   Fluorochrome   Clone  Specificity   
B220 Pacific Blue  RA3-082  CD45R (B cells and pDCs)  
CD3!  Alexa 700 or PE-Cy7  17A2  T cell lineage  
CD8"  PerCp Cy5.5 or PE  53-6.7  CD8!  
CD11b  Alexa 780  M1/70  !M"2  
CD11c  PerCp Cy5.5 or PE  HL3  !$"2 integrin   
CD115 PE  AF598  CSF-1R   
CD14  PerCp Cy5.5  Sa2-8  Myeloid lineage  
CD19  PE-Cy7  1D3   B cells  
CD24  FITC or PE  30-F1 Heat Stable Antigen 
CD40  PE  1C10  CD40  
NK1.1  Pacific Blue  PK136  CD161b/CD161c  
Ly6G  Alexa 647 or PE  1A8  Ly-6G  
Ly6C  Pacific Blue, Alexa 647 or PE  HK1.4  Ly-6C  
MMR  Alexa 488  15-2  CD206  
MHCII  Alexa 700 or PE  M5/114.15.2 MHCII I-A/E  
DEC-205  Alexa 647  NLDC  CD205  
MAC-3  PE  M3/84 CD107b 
GR-1  PE  RB6-8C5  Ly-6G/Ly-6C  
CD86  PE GL1 B7.2 
CD172"  APC or PE P84 SIRP alpha 
F4/80 PE BM8 F4/80 antigen 
CD135  PE A2F10 Flk2 
CD62L  PE MEL-14 L-selectin 
CD80  PE 16-10A1 B7.1 
CD45.1  PE-Cy7  A20 leukocyte common antigen 
CD45.2  FITC 104 leukocyte common antigen 
V#8.1/8.2  PE KJ16-133  CSP specific TCR 
V"2  PE B20.1 OVA specific TCR 
DC-SIGN Biotin 5H10 CIRE/CD209 
DC-SIGN Biotin LWC06 CIRE/CD209 
Table 2.1. Antibodies used for multicolor flow cytometry.  
 
2.4. Lipopolysaccharide and Bacteria 
 LPS from E. coli 055:B5 (Sigma) was injected i.v. (except for the in vivo 
presentation studies were LPS was injected s.c.) at 5 µg/mouse to induce Mo-
DCs. For optimal LPS activity, stocks were dissolved at 10 µg/µl or higher. Other 
TLR agonists were purchased from Invivogen and injected i.v. at 5 µg/mouse. 
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We also tested bacteria at a dose of 5x106 per mouse, both heat-killed and live 
bacteria (E. coli DH5!, B. subtilis). To evaluate presentation of proteins from 
bacteria, recombinant E. coli expressing OVA (5x106) was injected s.c. 
 
2.5. Generation of DCs from Bone marrow progenitors 
 Bone marrow cell suspensions were prepared as follows: femurs and tibias 
were removed from mice and kept in RPMI 1640 medium on ice. Muscles were 
separated from the bones using a sterile gauze pads.  The clean bones were 
immersed for 2 min in a petri dish containing 70% ethanol, and then washed 
twice with ice-cold RPMI 1640 medium. Male mice were preferentially used 
because they have bigger bones and therefore yield larger numbers of progenitor 
cells. Both ends (epiphyses) of each bone were cut off with scissors and the 
marrow was flushed out with 2 ml RPMI 1640 using a 3ml syringe and a 26G 
needle. Minced epiphyses together with the marrow obtained from the bone were 
resuspended with a pasteur pipette in order to break up the clumps. The cell 
suspension was passed through Nytex mesh (to remove particles) into a 15-or 
50-ml collection tube. After centrifugation 1500rpm for 10min, the pellet cells 
were lysed using ACK lysing buffer (Lonza) at 1ml/1x108 cells for 1min at rt. 
RPMI medium containing 5% FBS (Sigma) supplemented with 20 µg/ml 
gentamicin sulfate (Life Technologies) and 0.1% of "-mercaptoethanol 
(Invitrogen), also called R5 medium, was added to the top of the tube and 
centrifuged as previously described. Supernatant was removed and cells were 
stained for sorting (see next paragraph for monocytes isolation by cell sorting) or 
alternatively, total bone marrow were cultured in R5 with recombinant mouse 
Flt3L (Peprotech) at 400 ng/ml for 9 days and the equivalents of CD8#+ and 
CD8## spleen DCs were sorted as CD24high CD11blow and CD24low CD11bhigh 
cells, respectively (Naik et al., 2010) (Figure 2.3C). 
 Monocytes were sorted on a FACSAria (BD Biosciences) as SSClow, 
CD11bhigh, Ly6Chigh or as Ly6G#, CD11bhigh, Ly6Chigh cells, the latter ensuring 
higher yields. To generate Mo-DCs, monocytes were cultured with cytokines (M-
CSF, GM-CSF, GM-CSF, IL-4; PeproTech) at 20 ng/ml in R5. At 4–7 days, non-
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adherent cells were removed to test function, or for M-CSF, adherent cells were 
recovered with Cellstripper nonenzymatic cell dissociation solution (Mediatech).  
 
2.6. Monocyte and Bone Marrow Transfer 
 Sorted bone marrow monocytes from CD45.2+ strain of mice were 
transferred to 4-to 6-week CD45.1+ mice (>8 weeks gave poor results) at 2x106 
cells/mouse. For mixed chimeras, 50:50 mixtures of knockout (KO) and WT total 
bone marrow cells were injected i.v. into lethally irradiated mice (5.5 Gy twice, 3 
hr apart). To deplete monocytes, diphtheria toxin (Sigma, stock kept at 1 µg/µl, 
and stored at #80°C) was diluted in PBS and injected i.v. to LysMcre % iDTR 
mice at 25 ng/g weight (%500 ng/mouse). 
 
2.7. BrdU labeling 
 Mice were maintained on water containing 0.8 mg/ml of BrdUfor 4 days 
before the experiment. Mice were then injected intraperitoneal with BrdU (2 mg 
per mouse) together with LPS and MMD3 Alexa 647 antibody given i.v.. 12-24h 
after the injections skin draining lymph nodes were stained according to the 
instruction manual from the BD BrdU staining kit with DNase treatment 
 
2.8. Lymph node and spleen cell suspensions  
 To label Mo-DCs in vivo, we injected 10 µg of Alexa 647-MMD3 !-DC-SIGN 
or control mouse IgG2c mAb along with LPS. Mice were sacrificed 12h-24h after 
the injections and organs were removed. Skin draining lymph nodes include 
polipteal, inguinal, axillary and cervical. Lymph nodes and spleens were minced 
separately in HBSS with Ca2+ (GIBCO Invitrogen) supplemented with 
collagenase D (400 U/ml) and 50µg/ml DNAseI (Roche). The cells were 
incubated for 25 min at 37°C. A total of 5 mM EDTA (Gibco) was added for the 
last 5 min. For spleen cell suspensions, red blood cells were lysed using ACK 
buffer (Lonza), and samples were passed through a nylon mesh to removed 
undigested material.  
 For flow cytometry, nonspecific binding was first blocked with 2.4G2 
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supernatant anti-FcR II/III, and then cells were stained at 4°C in PBS/2% FBS 
(FACS buffer). Cells were stained with different cocktails of mAbs and gated as 
shown in the gating strategy regarding the different experiments. Multiparameter 
acquisition was done on an LSR II (Becton Dickinson), followed by analysis with 
FlowJo (TreeStar). 
 
2.9. Microscopy 
 10 µm OCT-embedded lymph node sections were acetone-fixed, stained 
with B220-Alexa 647 for B cell areas in confocal microscopy (LSM510, Zeiss). 
We also used injection of 30 µg Alexa 488 MMD3 anti-DC-SIGN or isotype 
control mAb i.v. to detect Mo-DCs in the tissue sections. Tissues were fixed in 
4% HCHO/PBS for 20 min, then 0.5% Triton X-100 for 15 min, and stained with 
rabbit anti-Alexa 488 and anti-rabbit HRP using TSA Alexa 488.  
 For live-cell differential interference contrast (DIC) imaging, Mo-DCs were 
seeded on glass bottom culture dishes (MatTek) and examined in an Olympus 
LCV110U incubator fluorescence microscope. Confocal and live-cell images 
were analyzed with MetaMorph software (Universal Imaging). 
 
2.10. Antigen Presentation 
 T cells specific for OVA (OT-I, OT-II) or malarial (P. yoeli) 
circumsporozoite protein (CSP) were cultured with graded doses of DCs or B 
cells. OVA (LPS-free, Seikagaku Corp.) or CSP was added in graded doses but 
usually at 40 µg/ml in vitro, or the proteins were injected for 2 hr in vivo 
(50 µg/footpad) during LPS mobilization of Mo-DCs. In some experiments, we 
used irradiated CHO cells stably transduced with OVA as the source of antigen. 
Splenic transgenic T cells were enriched after Fc block by excluding B220+, 
F4/80+, NK1.1+, I-Ab+, and CD4+ or CD8+ T cells using anti-rat IgG Dynabeads 
(Invitrogen), labeled with 5 µM CFSE (Invitrogen) and added to 96 well round 
bottom plates at 50,000/well. After 3 days for OT-I or 4 days for OT-II and CSP 
CD8+ Tg T cells, proliferation of live (Aqua dye negative, Invitrogen) T cells was 
evaluated by CFSE dilution and staining with mAb to V!2 for the OT-I or OT-II 
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TCR and V"8.1/8.2 for CSP. For the MLR, DCs from C57BL/6 mice were added 
in graded doses to CFSE-labeled BALB/c T cells 50,000/well (NK1.1, I-Ad, B220, 
F4/80 negative cells) and assayed at day 4. 
 
2.11. Quantitative PCR for TLR and CD14 Expression by 
Monocytes and Mo-DCs 
 Taqman probes (AssayID) were used for TLR4 (Mm00445273_m1), TLR2 
(Mm00442346_m1), TLR3 (Mm00628112_m1), TLR7(Mm00446590_m1), TLR9 
(Mm00446193_m1), and CD14(Mm00438094_g1) from Applied Biosystems. The 
relative expression was normalized by TATA-box binding protein (TBP) 
housekeeping gene expression. All qPCR experiments were performed with 
LightCycler 480 Real-Time PCR System (Roche). 
 
2.12. Microarray analysis 
 Different subsets of lymph node DCs were sorted as described above. Total 
RNA from two DC populations - DC-SIGN+ (Mo-DCs) and DEC-205+ - was 
isolated with Trizol LS reagent (Invitrogen). Microarray experiments were 
performed using MouseRef-8 v2.0 Expression BeadChip (Affymetrix). 
GeneSpring GX 11.0 (Angilent) was used for data analysis. Normalization was 
performed using median correction program, and the selected genes were 
analyzed in terms of differential expression. 
 
2.13. Leishmania infections 
 The parasites used were the clone line Friedlin VI derived from the L. major 
human isolate MHOM/IL/80/Friedlin. Promastigotes were maintained in vitro at 
26°C in M199 (Gibco) supplemented with 10% FBS (Invitrogen), 10mM Adenin, 
PenStrep 100x, Hemin, Biotin and NaHCO3 7.5%. For infection of mice, 2x106 
stationary phase metacyclic promastigotes were injected s.c. into the right hind 
footpad. The outcome of the infection was assessed by measuring the thickness 
of the infected footpads with a Vernier caliper.  
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3.1. Production of mouse DC-SIGN/CD209a monoclonal antibody 
 In our laboratory, we have recently reported the production of a mouse 
IgG2c/kappa DC-SIGN antibody, named MMD3, which could recognize an 
eptitope on the extracellular region of the DC-SIGN/CD209a receptor in the 
mouse (Cheong et al., 2010).  
 Hybridoma cells secreting MMD3 or MIC-G2c (IgG2c/kappa antibody with 
unknown specificity that was used as a isotype control) antibodies were 
expanded using rolling bottle method (Bodeus et al., 1985) and purified using 
protein G beads. The amount of protein obtained was ~2.5mg/L of culture. When 
analyzed by SDS-page and Western Blot, 2 bands were detected corresponding 
to the expected heavy and light chain of the IgG molecule (Figure 3.1A). The 
antibodies were then labeled with Alexa 647 and tested for binding to stable 
transfectant Chinese hamster ovary (CHO) cells that express the DC-SIGN 
receptor. As shown in Figure 3.1 the produced antibody bound appropriately to 
CHO-DC-SIGN cells (Figure 3.1B colored histograms), but not to untransfected 
CHO (CHO/Neo), while the control IgG2c did not bind to any of the cells (Figure 
3.1B grey histograms). This experiment also allowed us to test the efficacy of the 
labeling with the Alexa 647 fluorochrome. A strong fluorescence-activated cell-
sorting (FACS) signal is detected on the Alexa 647 laser after binding of MMD3 
mAb to DC-SIGN expressed on CHO-cells. This signal is specific because is not 
detected when we used the Isotype control IgG2c A647 mAb and because the 
intensity of the fluorescence decreases with the dilution on the MMD3 mAb 
concentration (Figure 3.1B low left histogram) 
 
3.2. Comparison of different monoclonal antibodies available 
against the mouse DC-SIGN/CD209a extracellular domain 
 We then compared our “home made” mouse MMD3 mAb with two other 
commercially available mAbs described to react with the mouse DC-SIGN, which 
are 5H10 and LWC06 from eBioscience (both rat IgG2a/kappa). To this end, we 
used again stable CHO/DC-SIGN or CHO/SIGN-R1 (used as a negative control) 
cells, that were incubate with each mAbs pre-labeled with biotin, then detected 
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with streptavidin APC as a secondary Ab and analyzed by FACS. Some samples 
were also subjected to fixation using a solution containing paraformaldehyde in 
order to see the effects of this treatment in the binding of the mAb with the 
receptor. The results showed that all the mAbs bound specifically to CHO/DC-
SIGN but not CHO/SIGN-R1 cells, but the fluorescence intensity is higher when 
using the MMD3. The difference becomes more prominent after fixation of the 
cells, where the intensity of the staining is better using MMD3 compared with the 
other 2 rat mAbs (Figure 3.1C). This prompted the investigation of this lectin 
receptor using the newly produced mouse DC-SIGN/CD209a mAb. 
Figure 3.1. Quality control for the produced mAbs after labelling  
(A) On the left: Coomassie-stained 10% (vol/vol) SDS/PAGE reducing gel comparing MMD3 and 
Isotype control mAbs with a protein molecular weight marker (in kilo daltons). Right: Western blot 
of the produced mAbs using HRP-conjugated !-mouse IgG. (B) Binding to CHO/mouse DC-SIGN 
and control CHO Neo cells (top left and right, respectively) using graded doses (0.03-3µg) of 
mAbs and anti-mouse IgG PE. The low panel shows the intensity of the signal on the Alexa 647 
red laser. Labeling was assessed by FACS. (C) Comparison of different anti-DC-SIGN mAbs. 
Anti-DC-SIGN Biotin mAbs that have been previously reported were compared with the newly 
produced MMD3 mAb in CHO/DC-SIGN or CHO/SIGN-R1 cells at 3 µg/ml with (lower panel) or 
without fixation of the cells (upper panel). Streptavidin-APC was used. 
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3.3. DC-SIGN/CD209a is a specific marker for Bone Marrow 
derived Mo-DCs 
 To determine if the MMD3 mAb to the mouse DC-SIGN/CD209a could 
identify in vitro derived Mo-DCs, as occurs in the human system (Geijtenbeek et 
al., 2000c), we purified by cell sorting monocytes from the bone marrow into 
SSClow Ly6Chigh and CD11b+ cells (Figure 3.2A) (Naik et al., 2006) and cultured 
them with two cytokines, GM-CSF and IL-4. We first confirmed that fresh bone 
marrow monocytes and granulocytes did not react with mAbs to DC-SIGN, MHC 
II, or CD11c (Figure 3.2B). After 4-7 days of culture in GM-CSF and IL-4, we 
could recover ~80% of the plated cells. At this point, most of the cultured 
monocytes had converted into large non-adherent cells that extended and 
retracted sheet-like processes in several directions from the cell body (Figure 
3.2C left panel), which is the hallmark, probing morphology of DCs (Steinman 
and Cohn, 1973) (Lindquist et al., 2004). These cells were also strongly reactive 
with mAbs to DC-SIGN, MHC II, or CD11c (Figure 3.2C pseudocolor FACS 
plots), and further designated as monocyte-derived dendritic cells (Mo-DCs). 
 We then compared in terms of expression of surface receptors, bone 
marrow monocytes and Mo-DCs obtained after culture in vitro with GM-CSF and 
IL-4, with spleenic monocytes and cDCs gatted as shown in Figure 3.2D. We 
found that Mo-DCs, like splenic DCs lacked M-CSF receptor or CD115 a key 
receptor for monocyte development, whereas both marrow and splenic 
monocytes expressed CD115 (Figure 3.2E green arrow), Splenic cDCs but not 
Mo-DCs expressed CD135, the receptor for Flt3L, a major hematopoietin for the 
development of DCs derived from non-monocytic precursors (Figure 3.2E red 
arrow). During differentiation, Mo-DCs also lost the Gr-1 and Ly6C markers of 
monocytes and reduced the levels of F4/80 but retained high expression of 
CD11b and CD172a found on both monocytes and DEC# spleen DCs. 
Monocytes and Mo-DCs lacked CD8!, expressed by the DEC+ subset of splenic 
DCs. In common, Mo-DCs and DEC+ splenic DCs expressed high levels of CD24 
(Figure 3.2E). MAC-3, a marker for macrophages was not expressed by any of 
the cell subsets.  
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Figure 3.2. DCs Derived from Marrow Monocytes Express DC-SIGN 
(A) Monocyte and granulocyte sorting strategy of bone marrow cell suspensions stained with 
mAbs to Ly6C and CD11b. SSClo single cells were gated and Ly6Chi and Ly6Cinter, CD11b+ cells 
were sorted as monocytes and granulocytes respectively (as gated on the plot on the right). (B) 
Purified monocytes or granulocytes stained for DC markers CD11c, MHCII, and DC-SIGN (C) 
Sorted marrow monocytes (as in (A)) were cultured in GM-CSF and IL-4 for 4–7 days. (Left) DIC 
image with typical dendritic morphology. (Right) MHC II, CD11c, DC-SIGN (A647-MMD3) and 
MMR expression on Mo-DCs. (D) Gating strategy used to define different cell populations in the 
mouse spleen. Dead cells, doublets, and CD19+CD3+ cells were first excluded from the analysis. 
In the CD11chigh population we analyzed 2 subsets of classical DCs: DEC+ and DEC-. Monocytes 
were found in the CD11c-CD11bhigh population after gating out the granulocytes (characterized by 
the expression of Ly6G) and using the CD115 surface marker. (E) Surface markers on 
monocytes, GM-CSF/IL-4-induced Mo-DCs, and different spleen cell populations. [A to C: Data 
obtained by Cheolho Cheong and included in this thesis with permission]. 
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In the overall, these data indicate that Mo-DCs acquire many surface features of 
splenic DCs except that Mo-DCs express DC-SIGN and lack CD135. 
 We used the mixed leukocyte reaction (MLR), a useful assay to show the 
immune-initiating capacity of DCs (Steinman and Witmer, 1978), to test if DC-
SIGN+ Mo-DCs could induce proliferation of syngeneic T cells. In these and all 
the T cell studies that will be further described, we used CSFE-labeled T cells to 
monitor the expansion of dividing or CFSElow T cells. Mo-DCs stimulated a strong 
MLR, but only when cultured in the presence of GM-CSF and IL-4, whereas 
monocytes cultured under other conditions were weak (GM-CSF) or inactive (IL-
4, M-CSF, Flt3-L) (Figure 3.3A bar graph on the right). 
 To evaluate presentation of protein antigens, we used two different TCR 
transgenic models as a source of responder T cells: the OT-I, referring to the 
Ovalbumin (OVA)-specific, class I-restricted TCR cells, and the YA26, 
corresponding to the malaria circumsporozoite protein (CSP) CD8+ TCR specific 
cells. First we compared Mo-DCs derived from GM-CSF+IL-4 cultures with 
splenic DCs (DEC-205+ and DEC-205#, corresponding to CD8!+ and CD8!# DCs 
and sorted as described on the top of Figure 3.3B) in their capacity to cross-
present antigens in vitro. For these assays, we used 40 µg/ml of CSP  
(expressed in bacteria), or Ovalbumin (OVA) in the form of soluble proteins. The 
Mo-DCs were superior in the cross presentation of both CSP (which is a non-
glycosylated protein) and OVA (which contains two N-glycosylation sites) when 
using graded doses of each type of DC (green line Figure 3.3B graphs).  
 Because Mo-DCs are likely to be mature due to the presence of GM-CSF 
and IL-4 in the culture for 5-7days, we used a more relevant comparison with 
classical DCs that had also been developed from in vitro bone marrow cultures, 
but using a Flt3L culture system as shown in Figure 3.3C top row. Over a range 
of protein concentrations and cell ratios, Mo-DCs were superior cross-presenting 
cells relative to in vitro Flt3L expanded, CD8#+, and CD8## DCs (green line on 
Figure 3.3C graphs).  
 Dead-cell-associated proteins are an important source of antigens for cross-
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presentation by DCs. In mice, CD8#+ splenic DCs have been described as the 
specialized population for cross-presentation, although such feature may not be 
attributed to an exclusive ability of these cells to capture exogenous antigens 
(Schnorrer et al., 2006) but to their high expression of the DEC-205 lectin 
(Bonifaz et al., 2004; Boscardin et al., 2006; Trumpfheller et al., 2006). Cross-
presentation of dead and dying cells is of special interest in the context of tumor 
immunology. Therefore, we also tested the capacity of Mo-DCs to cross-present 
antigens associated with dead cells. We used a CHO-cell line that was stably 
transfected in order to express the OVA protein and we induced apoptosis of 
these cells by UV irradiation. Using different DC:T cell ratios we showed that the 
Mo-DCs were still superior to CD8#+ DCs when irradiated OVA-CHO cells were 
used as the antigen (green line on Figure 3.3D).  
 Finally, to formally prove that the Mo-DCs derived from in vitro cultured BM 
monocytes were fully differentiated APCs, we also tested their capacity to 
present antigens in the context of MHCII. We used OT-II OVA specific TCR 
transgenic CD4+ T cells as responders that were cultured with different 
concentrations of DCs and using 40µg/ml of soluble protein. In this context we 
also compared Mo-DCs with splenic DCs. CD8#- DCs have been considered the 
most efficient cell subsets in presenting antigens to MHC class II-restricted T 
cells (Dudziak et al., 2007). However, Mo-DCs were superior to any other cell 
subset tested in the activation of CD4+ T cell proliferation (green line on Figure 
3.3E).  
 Thus in vitro derived Mo-DCs are marked by DC-SIGN and are functionally 
strong APCs, including for cross-presentation. 
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Figure 3.3 continue on next page           
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Figure 3.3. in vitro differentiated DC-SIGN+ MoDCs are potent APCs 
(A) Top row shows the phenotype of the Mo-DCs used to stimulate T cells in the following 
assays. Bone marrow monocytes from C57BL/6 mice were cultured for 4–5 days with different 
cytokines (Flt3L, IL-4, GM-CSF, M-CSF or GM-CSF+IL-4). After this cultured period Mo-DCs 
were sorted and added in triplicate wells at 1:10 ratio to BALB/C T cells labeled with CFSE for 5 
days. On the left: gating strategy used to study CFSE dilution and follow T cell proliferation. On 
the right: summary of the data representing T cell proliferation in the presence of different sources 
of DCs (B) Top row: gating strategy used to sort B cells (CD19+) and DCs from the mouse 
spleens. Middle row: gating strategy used to measure CFSElow T cells that proliferate on antigen 
presentation assays. Line graphs summarize the presentation of CSP or OVA soluble proteins 
added to the cultures in vitro (40 µg/ml) to TCR transgenic T cells by graded doses of Mo-DCs or 
B cells, DEC+ and DEC# DCs from spleens (C) Flt3L was used to generate cell subsets 
homologous to CD8+ (CD24hi CD11blow) and CD8- (CD24int, CD11bhigh) splenic DCs sorted as 
represented in the top row plots and used to compare their antigen presenting function to Mo-
DCs. The line graphs summarizes the presentation of CSP added at different concentrations (on 
the x-axis) to TCR transgenic T cells by graded doses of DCs. (D) Presentation of stably 
transduced,irradiated CHO-OVA cells by graded doses of different populations of DCs (DC:T cell 
ratio on the x-axis) that were generated in vitro from bone marrow cells, including the equivalents 
of CD8+ and CD8# cDCs from Flt3L in vitro cultures (as in C). (E) As is (B) but OT-II OVA specific 
CD4+ T cells were used in order to assay antigen presentation through MHCII. The data shown is 
representative of 2-3 experiments and the error bars correspond to the standard deviation of 
triplicate wells/condition.  
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Figure 3.4 continue on next page 
3.4. TLR4 Agonists Rapidly Recruit DC-SIGN+ Cells to the T Cell 
Area of LNs 
 To find out if comparable Mo-DCs develop in vivo in response to microbial 
stimuli, we treated mice intravenously (i.v.) with agonists for different TLRs and 
looked for DC-SIGN/CD209a+ cells in LNs 12–24 hr later. However, the problem 
we faced was that most DC-SIGN protein is expressed inside the cell and not on 
the cell surface, preventing the identification labeled cells after surface staining. 
To overcome this obstacle, during injection of LPS (or on PBS controls), we also 
included 10 µg of Alexa dye-labeled MMD3 anti-DC-SIGN mAb, or isotype-
matched control mAb, to allow the DC-SIGN+ cells to take up the fluorescent 
mAb. To identify DCs by flow cytometry we prepare cell suspensions from 
different peripheral lymphoid organs. The cells were then gated on live, 
lymphocyte-negative (includes a mix of CD3, CD19, B220 and NK1.1 positive 
cells) and CD11c+ (Figure 3.4A top row). When we treated mice with LPS, we 
observed a 10-fold increase on DC-SIGN/CD209a+ cells in the skin-draining 
lymph nodes comparing with the naïve controls, but not in the spleen or the 
mesenteric lymph nodes (Figure 3.4A lower panel).  
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Figure 3.4. Mobilization of DC-SIGN+ Mo-DCs to the T Cell Areas of the Skin 
Draining Lymph Nodes 
(A) Top row: gating strategy used to identify DC-SIGN+ dendritic cells in different lymphoid 
organs. Cells from the skin draining lymph nodes (including popliteal, inguinal, axial and cervical), 
spleen and mesentheric lymph nodes were assayed. We compared PBS with LPS treated mice 
(5 µg i.v.) that were injected i.v. with 10 µg of !-DC-SIGN-Alexa 647 mAb.. 12-24h later, cell 
suspensions were prepared and stained for FACS analyses. Dead cells, lymphocytes (CD3+ and 
CD19+) as well as NK cells (NK1.1+) and PDCs (B220+) were excluded and CD11c+ cells were 
studied for expression of DC-SIGN. (B) TLR4-competent (C3H/HeN) and TLR4 mutant 
(C3H/HeJ) mice were compared for expression of DC-SIGN. (C) As in A but mice were injected 
with 5 µg of different TLR agonist. (D) Lymph node sections from PBS or LPS-treated mice were 
stained with the indicated mAb. 400% magnification. [B to D: Data obtained by Cheolho Cheong 
and included in this thesis with permission]. 
 
 The expansion in the number of DC-SIGN/CD209a+ cells was observed in 
C3H/HeN but not C3H/HeJ TLR4 mutant mice, indicating a need for TLR4 
(Figure 3.4B compare top and bottom right). However, DC-SIGN/CD209a+ cells 
did not expand in response to other TLR agonists like Pam3CSK4, poly(I:C), 
Flagellin, R848, and CpG, for TLR2, 3, 5, 7/8, and 9, respectively (Figure 3.4C). 
 To determine whether Mo-DCs localize into the T cell areas like authentic 
DCs, we used the mAbs to the mouse DC-SIGN to label lymph node sections. In 
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PBS mice, there were relatively few DC-SIGN+ cells, mainly in interfollicular 
regions, between B220+ B cell follicles (Figure 3.4D). However, 12 hr after LPS 
was given i.v., DC-SIGN+ cells were abundant and localized to T cell areas.  
Therefore, DC-SIGN marks abundant cells in the T cell areas of the skin draining 
lymph nodes from LPS-treated mice, regions in which DCs have been shown to 
present antigens to circulating antigen-specific T cells (Stoll et al., 2002), 
(Mempel et al., 2004), (Miller et al., 2004) and (Shakhar et al., 2005). 
 
3.5. Mo-DCs Can Be Selectively Labeled with Injected Anti-DC-
SIGN/CD209a Antibody and Isolated from Classical DCs in LPS 
treated Skin draining Lymph Nodes 
 To compare the properties of LPS-mobilized DC-SIGN+ cells with other 
DC subsets present in the mouse skin draining LNs, we needed a strategy to 
separate the different cell subtypes. Therefore, we added an anti-DEC-205 mAb 
to our previously described mAbs mix in order to label classical DC. This strategy 
allowed us to distinguish 3 DC population from skin draining LNs of LPS-treated 
mice: DEC-205+ and DEC-205# populations, both lacking DC-SIGN and a DC-
SIGN+ subset expressing intermediate levels of DEC-205. (Figure 3.5A far right 
plot).  
 In the skin draining LNs from mice injected with LPS plus-labeled MMD3 
mAb, there was a specifically stained DC-SIGN+ population, as there was no 
staining if isotype control mAb was injected or if we studied DC-SIGN#/# mice 
(Figure 3.5B). In all the further experiments using LPS we always confirmed the 
activation of the immune cells by checking CD86 upregulation on splenic DCs 
(Figure 3.5B left histograms). 
 Labeling with MMD3 was comparable in wildtype (WT) and Fc receptor 
&#/# mice, further indicating that the uptake of the mAb was not Fc mediated 
(Figure 3.5C). 
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Figure 3.5. DC-SIGN+ Mo-DCs Are Induced upon Treatment with LPS                                   
(A) Gating strategy used for the separation of three lymph node DC populations on LPS treated 
mice. Skin-draining LN cells were stained for lymphocyte markers (CD3, CD19, NK1-1), CD11c, 
and DEC-205. Isotypes for DC-SIGN and DEC-205 are mouse IgG2c and rat IgG2a, respectively. 
(B) Specific labeling of DC-SIGN/CD209a+ cells by anti-MMD3 mAb injection in PBS and LPS 
treated WT or DC-SIGN#/# mice. LN cell suspensions were gated as in A and CD11c+ cells were 
analyzed for DC-SIGN/CD209a (or isotype control) vs DEC-205/CD205 or CD8#. On the right: 
The systemic injection of LPS was confirmed by analyzing upregulation of CD86 on DCs. (C) As 
in (B), but we compared WT and FcR&#/# mice. (D) Expression of maturation markers and 
MMR/CD206 on the three DC populations defined (E) Representative morphology (DIC images) 
of DC-SIGN+ cells sorted from LNs of LPS-treated mice as in (B). 600% magnification. (F) The 3 
DC populations were stained and analyzed for the expression of different markers using PE-
mAbs. 
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 When tested for surface markers, all three populations had high levels of 
MHC II, which is expected of DCs, and all expressed CD40, 80, and 86 with the 
DC-SIGN+ and DEC-205+ subsets having the highest levels (Figure 3.5D). We 
also assessed mannose receptor (MMR/CD206) because both CD206 (Sallusto 
et al., 1995) and DC-SIGN/CD209 (Geijtenbeek et al., 2000c) are expressed by 
human Mo-DCs, and also because both markers co-labeled in vitro differentiated 
mouse Mo-DCs, as previously shown (Figure 3.2E). In this regard, we confirmed 
that DC-SIGN+ cells differentiated in vivo upon LPS stimulation also co-label with 
MMR/CD206 (Figure 3.5D far right plot). Next, we verified that the sorted DC -
SIGN+ cells had the probing morphology of DC (Figure 3.5E). All three DC 
populations likewise failed to stain for CD115, the M-CSF receptor know to be 
expressed mainly on cells of monocyte/macrophage lineage. DC-SIGN+ cells 
lacked CD135, which was in contrast expressed by the other two DC populations 
(Figure 3.5F). Like DEC-205# DCs, DC-SIGN+ cells were CD11b+ and 
CD172!/SIRP!high, F4/80+, CD24low, and CD8## (Figure 3.5F).  
 Thus skin draining LNs from LPS-treated mice have three populations: 
population #1 corresponds to DC-SIGN/CD209a+ DCs, which we will show derive 
from monocytes, whereas population #2 corresponds to DEC-205+ (including 
CD8#+, Figure 3.5F orange arrow). Regarding population #3 we think represents 
DEC-205# resident DCs but we could not fully confirm this hypothesis due to the 
lack of specific markers to define this DC subset in the LNs. 
 To test if LPS-bearing bacteria could also induce expansion of DC-SIGN+ 
cell in the skin draining LNs as observed with LPS, we injected the labeled 
MMD3 mAb together with either dead or live gram-negative E. coli or gram-
positive B. subtilis. Either dead or live E. coli, but not dead or live B. subtilis, 
mobilized DC-SIGN+ cells and upregulated CD86 on splenic DCs if injected i.v. 
(Figure 3.6A and B).  
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Figure 3.6. DC-SIGN+ Mo-DCs Are Induced upon Treatment with LPS 
bearing bacteria 
(A) As in 2.5A but we injected 5 % 106 live or dead E. coli or B. subtilis i.v. along with 10 µg of 
MMD3 anti-DC SIGN mAb 12 hr prior the preparation of lymph node cell suspensions. (B) Splenic 
DCs were stained for upregulation of CD86 as in (2.5B).  
 
 These data indicate that cells with the morphology and markers of Mo-
DCs accumulate in vivo in response to LPS or LPS bearing bacteria. Mouse Mo-
DCs resemble CD8## DEC-205# resident DC except for selective expression of 
DC-SIGN/CD209a and MMR/CD206 lectins (Figure 3.5D, Figure 3.7A and B), 
two uptake receptors also abundant on human Mo-DCs (Sallusto et al., 1995) 
and (Granelli-Piperno et al., 2005). Because DC-SIGN and MMR co-labeled 
population #1 on the mouse skin draining lymph nodes (Figure 3.7A and B), one 
of the two markers will be use in the following experiments to quantify Mo-DCs.  
 
 
 
 
 
Figure 3.7. DC-SIGN+ Mo-DCs Induced upon Treatment with LPS also 
expresses the Mannose receptor/CD206 
(A) Mice were treated with LPS as previously described and live, lymphocyte# CD11c+ cells were 
analyzed for the expression of DC-SIGN vs MMR/CD206 (B) Tissue sections of skin draining LNs 
after injecting either PBS or 5 µg LPS i.v. and the MMD3 anti-DC-SIGN mAb (represented in 
green), and counterstaining for B cells (blue, anti-B220)  and MMR/CD206 (red). 100% 
magnification. 
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3.6. DC-SIGN+ cells in LPS-Stimulated Lymph Nodes Derive from 
Monocytes 
To determine whether DC-SIGN+ cells mobilized upon LPS injection 
derived from a truly monocyte precursor cell in vivo, we injected i.v. 2 % 106 bone 
marrow sorted monocytes (as in Figure 3.2A) from CD45.2+ mice into CD45.1+ 
hosts. Next day, the mice were injected i.v. with 5 µg of LPS. 24h later, skin-
draining LNs were labeled with MMR/CD206 mAb in order to quantify cell 
recruitment by flow cytometry (Figure 3.8A). In three experiments, with three 
mice each, LPS induced an increase in CD45.2+ donor-derived, MMR/CD206+ 
cells, whereas these donor-derived cells were absent in the nodes of PBS mice 
(Figure 3.8B). 
Figure 3.8. Bone marrow monocytes can give rise to Mo-DCs marked by 
MMR/CD206 expression. 
(A) Scheme summarizing the experimental set-up. CD45.2 monocytes were transferred i.v. into 
CD45.1 hosts. 24h later, PBS or 5 µg of LPS was injected i.v. and 1 day later, CD206+ DCs 
expressing CD45.2  were enumerated. (B) FACS plots from individual mouse. First row shows the 
expression of MMR on CD11c+ cells and second row shows the frequency and number (on the 
top of each plot) of CD45.2 cells originated from donor monocytes inside the MMR+ CD11c+ gate. 
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On the right: column graph summarizes the number of CD11c+MMR+CD45.2+ cells in each 
experimental mouse. The results are representative of one out of two similar experiments. [Data 
obtained by Cheolho Cheong and included in this thesis with permission]. 
 
  
 To establish the monocyte origin of LPS-recruited DC-SIGN+ by an 
alternative method, we focused on LysMcre % iDTR mice. This strain was 
obtained by crossing a homozygous male expressing the Cre recombinase under 
the control of the murine M lysozyme gene (LysMCre) with a female homozygous 
for the simian Diphtheria Toxin Receptor (DTR; from simian Hbegf). The 
widespread expression of DTR in iDTR mice is blocked by an upstream loxP-
flanked STOP sequence. But, in the progeny (LysMcre % iDTR mice) DTR 
expression is allowed due to the action of the Cre enzyme that “cuts” the STOP 
sequence between the two loxP sites (Buch et al., 2005). Cells expressing DTR 
will be however restricted to monocytes, macrophages and neutrophils where the 
M lysozyme gene is specifically expressed and Cre is present (Clausen et al., 
1999) (Goren et al., 2009). These cells are then susceptible to ablation following 
Diphtheria toxin administration (Buch et al., 2005) (Figure 3.9A).  
 First we confirmed that a single dose of DT given i.v. could deplete ~80% 
of the monocytes population in the blood of LysMCre % iDTR mice, 12 hr later 
(Figure 3.9B). Likewise, in the LNs, DT-treated LPS-injected WT mice could 
normally mobilize CD11c+ DC-SIGN+ cells (Figure 3.9C, left plot, red arrow), but 
DT-treated LPS-injected LysMcre % iDTR mice failed to generate Mo-DCs. 
However, the classical monocyte-independent DC subset, marked by CD8# 
expression were normally represented in both strains and were not affected by 
DT treatment (Figure 3.8C left and right plots, green arrow). 
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Figure 3.9. Depletion of Monocytes and macrophages from the blood 
impedes mobilization of DC-SIGN+ Mo-DCs to the skin draining LNs upon 
LPS stimulation. 
 (A) General scheme of the LysMCre inducible DTR (iDTR) mouse model. The STOP cassette, 
which prohibits DTR expression, is removed by crossing the iDTR strain to a LysMCre-expressing 
mouse strain. Consecutive expression of the DTR renders macrophages and monocytes 
sensitive to cell death induced by injection of diphtheria toxin (Buch et al., 2005). (B) Top row. 
Gating strategy used to define monocyte populations in the blood. WT and LysMCre % iDTR mice 
were injected with DT, and 12 hr later, blood monocytes (Ly6G# CD115+ CD11b+ Ly6Chigh/low) 
were analyzed. Pseudo-plots show and example demonstrating how blood monocytes were 
depleted using the LysMCreiDTR system and on the column graph we show the quantification of 
the cells in WT and iDTR treated mice. (C) 24 hr after DT injection, 5 µg of LPS plus 10 µg of 
MMD3-Alexa 647 mAb were given i.v. and 12 hr later, skin-draining LN cells were analyzed as 
CD11c high and segregated into three DC populations to look for DC-SIGN+ Mo-DCs (red arrow) 
and CD8#+ classical DCs (green arrow). 
 
  
 This result suggests that DC-SIGN+ cells are derived from monocytes 
circulating in the blood, whereas classical DCs are not. Therefore DC-SIGN+ 
MMR+ cells expanded upon LPS injection will be, for now on, designated as Mo-
DCs. 
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 The spleen was recently recognized as a reservoir of monocytes that are 
mobilized in response to injury (Swirski et al., 2009). To test whether this organ 
was a source of the DC-SIGN+ Mo-DCs we studied splenectomized mice, were 
the spleen was surgically removed. As a control, we used sham-operated mice 
corresponding to animals submitted to the same surgical procedure as the 
experimental mice, except the removal of the spleen, in order to ensure that the 
result reflect the effects of the lack of the organ itself, and are not merely a 
consequence of the surgery. However after LPS injection, both groups normally 
mobilized Mo-DCs defined by the expression of MMR/CD206+ (Figure 3.10). 
  
 
 
 
 
Figure 2.10. The spleen is not required to generate Mo-DCs.  
Splenectomized mice were injected with PBS or LPS (5 µg) i.v. for 12 hr and Mo-DCs expressing  
MMR/CD206 staining were quantified. The graph shows the number of Mo-DCs gated on live, 
limphocyte#CD11c+MMR+ cells per 106 skin draining LN cells. 
 
  
 To selectively deplete classical DCs, we employed Flt3 receptor deficient 
mice (Flt3#/#), which lack classical DCs, but MDPs and pre-DCs are normally 
represented (Waskow et al., 2008). Ftl3 ligand deficient mice (Flt3L#/#) are also 
available but have a 50% reduction in the numbers of MDPs and CDPs 
comparing with wild type (McKenna et al., 2000) (Kingston et al., 2009). 
Therefore this mouse model was not used since we want to ensure that the 
precursor cell pool of monocytes was intact and normally represented.  
 First, we confirmed the deficiency of classical DCs of Flt3#/# mice. In the 
steady state skin draining LN the expression of CD11c and intermediate levels of 
MHCII characterize classical DCs. As shown in Figure 3.11A, this population is 
drastically reduced (~75%) in the KO mice comparing with WT, as well as the 
PDCs subset (CD11clow/MHCIIlow) (Waskow et al., 2008). In contrast, migratory 
DCs constantly travel from the periphery to the draining lymph nodes and 
therefore characterized by a high expression of MHCII, and are not affected by 
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the lack of the Flt3 receptor because they are not dependent on Flt3 ligand 
signaling for their maintenance and survival. When test for the capacity to 
mobilize Mo-DCs, LPS treatment leaded to comparable numbers MMR/CD206+ 
cells in Flt3#/# and WT mice (Figure 3.11B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11. Signaling through the cytokine tyrosine kinase receptor flt3 is 
dispensable for the formation of DC-SIGN+ Mo-DCs induced upon treatment 
with LPS  
(A) Skin draining LN DC subsets in steady state in WT and Flt3#/# mice. On the left: FACS plots of 
lymphocyte negative cells analyzed for CD11c versus MHC II expression. The name of the 
different DCs subsets is shown. Right: bar graph quantifies DC subset numbers per million of 
total LN cells. (B) WT and Flt3#/# mice were injected with PBS or 5 µg of LPS i.v. for 24 hr. Mo-
DCs were enumerated based on the expression of MMR/CD206. On the left: FACS plots of 
lymphocyte negative cells analyzed for CD11c versus MMR/CD206 expression. Right: bar graph 
summarizing the number of Mo-DCs per million of total LN cells acquired. The results shown 
represent one of two independent experiments with 2 mice per experimental group. [Data 
obtained by Cheolho Cheong and included in this thesis with permission]. 
 
  
 To examine the turnover of the in vivo formed MoDCs, we labeled mice 
with BrdU during the 12 hr treatment with LPS.  
 BrdU is used for nucleotide substitution to replace thymidine with uridine in 
the DNA structure of dividing cells of various types and therefore a useful 
compound for proliferation studies. In our experiments, no labeling was evident in 
DC-SIGN+ cells in contrast with a basal level detection of BrdU labeling on the 
other two DC subsets (Figure 3.12). Since BrDU uptake only reflects local 
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proliferation our results are in line with the current model of DC homestasis in the 
lymphoid organs where the classical DCs have the potential to divide in situ (Liu 
et al., 2007), in contrast with Mo-DCs that have no proliferation potential (Naik et 
al., 2006) (Ginhoux et al., 2006) (Merad and Manz, 2009).   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12. DC-SIGN+ Mo-DCs do not divide in situ upon LPS stimulation in 
skin draining LNs.  
Flow cytometry analysis of BrDU uptake by the 3 DCs populations 12h after i.p. injection with 
BrDU (2mg/ml). Numbers indicate frequency of BrdU+ cells in each cell subset. 
 
 All together the results described above provide considerable evidence for 
the monocyte origin of DC-SIGN+ DC in the LNs from LPS-treated mice. 
 
 
3.7. L-Selectin and CCR7 Are Required for LPS to Generate Mo-
DCs 
 To begin to identify mechanisms of Mo-DC mobilization, we evaluated the 
importance of L-selectin/CD62L, a lymph node homing molecule used by 
lymphocytes to enter the secondary lymphoid tissues via high endothelial 
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venules (Rosen, 2004). The involvement of this molecule in the mobilization of 
Mo-DCs was also suggested by the fact that pure BM monocytes expressed high 
levels of CD62L prior to become Mo-DCs (Figure 3.2F light blue histogram on 
the bottom). To test our hypothesis we blocked L- selectin in vivo with a specific 
antibody (Mel-14) or we treated mice with an isotype Ab control 1 hr prior to LPS 
injection. Treatment with Mel-14 blocked Mo-DC formation in the skin draining 
LNs, and thus DC-SIGN+ cells were not detected by immunolabeling of tissue 
sections or by FACS of cell suspensions (Figure 3.13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13 MEL-14/anti-CD62L mAb injection blocks mobilization of DC-
SIGN+ Mo-DCs upon LPS stimulation 
MEL-14 mAb to block L-selectin was given at 100µg/mouse i.v. 1 hr before injection with 5 µg of 
LPS plus 10 µg of MMD3-Alexa 647 mAb. 24 hr later, Top row: tissue sections of skin draining 
LNs were analyzed and stained for B cells with anti-B220 represented in blue. 100% 
magnification. MMD3 anti-DC-SIGN mAb is represented in green. Lower row: FACS analysis of 
cell suspensions gated on live, limphocyte# cells analyzed for expression of CD11c vs DC-SIGN. 
[Data obtained by Cheolho Cheong and included in this thesis with permission]. 
 
 
 Cell migration is also mediated by chemokines. To identify the 
requirement of chemokine receptors, we tested four distinct knockout mice. 
Accumulation of DC-SIGN+ Mo-DCs was critically dependent on CCR7 (Figure 
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3.14A). Only a partial but statistically significant decrease in Mo-DCs was noted 
in CCR2#/# mice (Figure 3.14B), whereas CCR5 and CCR6 were not necessary 
(Figure 3.14A). On the other hand, monocytes disappeared normally from the 
blood in LPS-treated CCR7#/# mice (Figure 3.14C), and CCR7 was not required 
to generate Mo-DCs in vitro (Figure 3.14D). We also verified that spleen DCs in 
the knockout mice responded normally to LPS by upregulating CD86 (Figure 
3.14E), suggesting that CCR7 is only required for the entry/differentiation of Mo-
DCs in the skin draining LNs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14. Mobilization of Mo-DCs primarily depends on CCR7 chemokine 
receptor 
(A) WT and different Chemokine receptor KO mice were injected with 5 µg of LPS i.v. 24 hr later 
skin draining LN cells were analyzed for Mo-DCs identified by the expression of MMR/CD206   
(B) CCR2#/# mice (n = 6) show a statistically significant reduction in mobilization of Mo-DCs by 
LPS. Mo-DCs number was normalized with the counts obtained in PBS mice in order to show fold 
change. Error bars = SD. (C) LPS treatment comparably and rapidly reduces blood monocytes in 
WT and CCR7#/# mice. Blood monocytes were stained as previously described (Figure 2.9B) and 
their numbers quantified (column graph on the right). (D) Normal development of CD11c+ MHCII+ 
Mo-DCs from CCR7#/# monocytes by culture in GM-CSF and IL-4. The histograms on the righ 
show the absence of CCR7 surface staining in the CCR7#/# Mo-DCs confirming the deficiency of 
the chemokine in the knockout cells. (E) Systemic injection of LPS was confirmed by CD86 
upregulation on spleen DCs. 
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 To establish the cell intrinsic requirement for CCR7, we made mixed BM 
chimeras with 50:50 ratio of WT and CCR7#/# donor cells, each marked with 
CD45.1 and CD45.2 respectively, and injected into CD45.1 WT hosts as shown 
in Figure 3.15A. Six weeks later, we certified chimerism in the blood and verify 
the 1:1 ratio of WT and KO cells injected into the irradiated hosts (Figure 3.15B). 
In order to expand Mo-DC we injected host mice with LPS greatly reducing the 
number of monocytes in the blood (Figure 3.15C), but only CD45.1+ WT cells 
and not CD45.2+ CCR7#/# cells formed Mo-DCs (Figure 3.15D), indicating that 
the need for CCR7 by Mo-DCs is cell intrinsic. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15. CCR7 dependence is intrinsic of the Mo-DCs. 
(A) Scheme summarizing the experimental protocol used in the BM chimeras. Host CD45.1 WT 
mice were lethally irradiated and reconstituted with CD45.1 (WT) and CD45.2 (CCR7#/#) at 1:1 
ratio. (B) Blood chimerism was confirmed 6 weeks after the transfer of the cells. (C) Mice were 
then injected with 5 µg of LPS plus 10 µg of MMD3-Alexa 647 mAb i.v. 12 hr after injections the 
blood was analyzed for the presence of monocytes that had largely disappeared. (D) Skin 
draining LNs were stained for lymphocyte markers (that were excluded from the gating) CD11c, 
DC-SIGN, CD45.1 and CD45.2 to show that Mo-DCs were mainly of WT in origin. [Data obtained 
by Cheolho Cheong and included in this thesis with permission]. 
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3.8. DC-SIGN+ Mo-DCs Efficiently Present Proteins Captured In 
Vivo to T Cells 
 To test the antigen-presenting functions of Mo-DCs mobilized in vivo to 
the inflamed skin draining LNs we sorted the three populations of CD11chigh DCs 
using DEC-205 and DC-SIGN as markers as shown in Figure 3.5A and test 
them in different T cell in vitro assays. We also used CD19+ B cells as a control 
because they can also act as APCs. All three DC subtypes from LPS-treated 
mice effectively stimulated allogeneic T cells in the MLR assay, with Mo-DCs 
being moderately more active and B cells totally inactive (Figure 3.16A line chart 
and pseudocolor plots illustrating the original FACS data). Surprisingly, Mo-DCs 
were comparable or superior to classical DCs in presenting two different proteins, 
OVA and CSP, to CD8+ and CD4+ TCR transgenic T cells (Figure 3.16B). Thus 
just like the Mo-DCs that can be generated in vitro by adding GM-CSF and IL-4 
to BM monocytes, LPS-mobilized Mo-DCs in vivo are as good or better 
presenting cells than classical DCs, including on cross-presentation. These T cell 
assays were performed by adding 40 µg/ml of the soluble antigen in the cultures. 
But, we were also interested to evaluate antigen capture in vivo. To this end, we 
injected soluble CSP or OVA protein s.c. after the administration of LPS. 2 hr 
later CSP/OVA injection we isolated the 3 DC populations as well as the B cells 
from the LN as previously described (Figure 3.16C top row). 
 When added in graded doses to TCR transgenic, CD4+ and CD8+ T cells 
without further antigen, Mo-DCs were again comparable or superior to the other 
two DCs subsets for both antigens, CSP and OVA (Figure 3.16C), showing that 
these cells can capture and present on both MHC I and II also in vivo.  
 To determine the type of T cell that was developing in response to 
antigen-presenting Mo-DCs, we collected the medium after 4 days of co-culture 
of OT-II CD4+ TCR transgenic T cells with Mo-DCs that had captured OVA 
in vivo. The Mo-DCs induced strong production of IFN-& and IL-2 but not IL-4, IL-
10, or IL-17 (Figure 3.16D), suggesting Th1 differentiation.  
 Finally, in order to evaluate presentation of bacterial associated antigens, 
we injected recombinant E. coli bacteria expressing OVA (or E. coli control). 
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Figure 3.16 continue on next page 
Twelve hours later, we isolated the 3 populations of DCs from the skin draining 
LNs. Mo-DCs were again in this setting, more effective than DEC-205+ classical 
cross-presenting DCs, whereas cells from the “double negative” subset did not 
cross-present bacteria associated antigens (Figure 3.16E). 
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Figure 3.16 The three types of DCs presented in the LPS-treated skin 
draining LNs can Efficiently Present Proteins to T Cells 
C57BL/6 or B6 % BALB/c F1 mice were injected i.v. with 5 µg LPS plus 10 µg of MMD3-Alexa 647 
mAb for 12 hr to isolate three DC fractions by cell sorting (>95% purity), as shown in the contour 
plot on the right (C). Graded doses of sorted DC populations were added to 50,000 CFSE-labeled 
T cells, and 3–4 days later, CFSElow T cells were counted. (A) MLR was assayed to verify DC 
activity. (B) As in (A), but 40 µg/ml of the indicated protein (on the top of each graph) was added 
to the cultures with the respective CFSE labeled TCR Tg T cells. (C) Scheme of the experimental 
protocol used to test presentation of antigens in vivo. Mice received 5 µg of LPS i.v. plus 10 µg of 
MMD3-Alexa 647 mAb 10h before injection of 50 µg of CSP or OVA protein s.c. in each paw. 2 hr 
after, DCs populations and B cells were isolated and co-cultured with CFSE labeled TCR Tg T 
cells. The results shown are representative of two experiments with triplicate wells for each 
condition. Line graphs summarize the average number of CFSElow T cells in triplicate wells. FACS 
plots are also shown. (D) As in (B), but ELISA was used to measure the indicated cytokines 
secreted to the medium during the 4 days cultures in which different types DC subsets were used 
to present OVA to OT-II CD4+ T cells. (E) 5–10 %106 live E. coli-OVA or control E. coli were 
injected s.c. with 10 µg MMD3 A647 mAb. 12 hr later, the three populations of LN DCs were 
isolated and used to stimulate OT-I CD8+ T cells. The data shown is representative of two 
independent experiments using triplicate wells for each condition. Error bars = SD. 
 
 
3.9. Mo-DCs Selectively Express CD14, a Needed Coreceptor for 
Trif-Dependent LPS Signaling 
 To begin to understand why LPS and gram-negative bacteria were 
superior agonists for mobilizing Mo-DCs, we compared by microarray gene 
profiling two of the three DC populations isolated from LPS-treated LNs, the 
DEC-205+ and DC-SIGN+ cells. Expression analyses focused on a particular 
panel of genes encoding different TLRs and TLR-mediated signaling molecules, 
and shows that DEC-205+ DCs express high levels of TLR3 as expected from 
previous studies with splenic DCs (Edwards et al., 2003) (Naik et al., 2005) but 
TLR4 and its co-receptor CD14 were markedly upregulated on DC-SIGN+ Mo-
DCs (Figure 3.17A). On the other hand, we also used quantitative PCR to 
! *#!
assess expression of various TLR genes in bone marrow monocytes and Mo-
DCs derived from in vitro cultures with GM-CSF and IL-4. Both cells expressed 
several TLRs. However, fully differentiated Mo-DCs show higher expression of 
TLR4 and CD14 comparing with pure monocytes (Figure 3.17B). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17 DC-SIGN+ Mo-DCs Selectively Express CD14 
(A) Heatmap of RNA microarray data showing expression of different TLRs and CD14 genes on 
triplicate samples of sorted DC-SIGN+ and DEC-205+ DCs from LPS treated skin draining LNs. 
Red represents upregulation of the expression level above mean of the gene across all samples, 
green represents expression lower than the mean (B) Quantitative PCR to assess expression of 
mRNA for TLRs and CD14 on sorted bone marrow monocytes and Mo-DCs. The relative 
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expression was normalized relatively to TATA-box binding protein (TBP) housekeeping gene 
expression. (C) Shows the gating strategy used to check CD14 expression in different cell 
subsets in the blood of naïve mice (D) CD14 staining was also evaluated in the different cell 
populations present on LPS-treated LNs, and showing selective expression on DC-SIGN+ Mo-
DCs (blue histogram) (E) As in D but CD14 expression (or isotype control) was analyzed on the 
lymphocyte negative CD11c+ cells relatively to DC-SIGN and DEC-205. 
  
 To pursue the contribution of the LPS co-receptor the CD14, we used a 
mouse anti-CD14 mAb to show that monocytes were selectively CD14+ in blood 
(Figure 3.17C), whereas among CD11c+ DCs in the skin draining LNs from LPS-
stimulated mice, only DC-SIGN+ cells stained for CD14 (Figure 3.17D and E). 
Therefore Mo-DCs can be defined also by expression of CD14. 
  
 When we studied CD14#/# mice, which lacked CD14 expression on splenic 
monocytes and did not respond to LPS by upregulation of CD86 by DCs (Figure 
3.18A), also failed to mobilize Mo-DCs to the skin draining LNs (Figure 3.18B). 
Unexpected was the fact that DC-SIGN is not a required receptor for the 
formation of the Mo-DCs. This coclusion was obtained from the studies using 
DC-SIGN deficient mice were Mo-DCs were normally represented and detected 
by double staining with MMR and CD14 markers (Figure 3.18C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.18 Binding of LPS to CD14 is indispensable for DC-SIGN+ Mo-DCs 
differentiation, but the DC-SIGN receptor is not required   
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 (A) Expression of CD14 (right) and CD86 (left) on splenic monocytes (gated as shown in Figure 
2.2D) and DCs respectively to show absence of CD14 stain and CD86 upregulation in CD14#/# 
mice. (B) LPS treated skin draining LNs from CD14 deficient mice lack DC-SIGN+ MoDCs 
comparing with the WT controls. Numbers of CD11c+ DC-SIGN+ cells are also represented. (C) 
Mo-DCs are recruited to the skin draining LNs of DC-SIGN knockout mice treated with LPS. In 
this case, Mo-DCs were stained ex-vivo with CD14 and MMR/CD206 antibodies. Splenic DCs 
from DC-SIGN deficient mice also responded to the LPS injection by upregulaton of the CD86. 
 
 CD14 is a known co-receptor for MyD88-independent, Trif-dependent 
TLR4-associated signaling cascade (Jiang et al., 2005). We then compared mice 
lacking the MyD88 and Trif adaptors for TLR4 signaling, where Trif, not MyD88, 
was essential for LPS to mobilize Mo-DCs (Figure 3.19A) and to upregulate 
CD86 on splenic DCs (Figure 3.19B). 
Figure 3.19. Recruitment of DC-SIGN+ Mo-DCs is Trif-Dependent 
(A) LPS treated skin draining LNs from MyD88/TRIF double deficient mice lack DC-SIGN+ Mo-
DCs but not MyD88 single knockout mice, as shown by the contour plots, compared with the 
WTcontrols. Numbers of CD11c+ DC-SIGN+ cells are also represented. (B) Expression of CD86 
on splenic DCs to show absence of upregulation in response to LPS when mice are lacking 
MyD88 and Trif but not MyD88 alone. 
 
 In addition, CD14+ cells accumulated with identical kinetics to DC-SIGN+ 
Mo-DCs, peaking at 24 hr when becoming the dominant DC subset in the LPS-
treated skin draining LNs (Figure 3.20).   
 
 
 
 
 
 
 
Figure 3.20. Kinetics of DC-SIGN+ DCs in LPS-treated skin draining LNs. 
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Mice were injected i.v. with 5 µg LPS at different time points. 10 µg of MMD3-Alexa 647 mAb was 
given also i.v. 12 hr before the preparation of of skin draining LNs cell suspensions for each time 
point. Contour plots show that Mo-DCs become dominant at 24 hr while DEC-205+ DCs recede. 
The line graph shows the quantification of DC-SIGN+ and CD14+ cells gated on live, lymphocyte 
negative, CD11c+. Mo-DCs numbers represent the average of two mice per time point. 
 
 Together, these data indicate that CD14, a co-receptor for TLR4, is 
upregulated by LPS and is essential for Mo-DC differentiation via Trif signaling. 
 To find out if selective expression of CD14 provided an independent 
strategy to isolate Mo-DCs after injecting antigens in vivo, we isolated Mo-DCs 
that were labeled with CD14 ex vivo with DC-SIGN mAb in vivo labeling. With 
either approach, Mo-DCs were similar and superior cross-presenting DCs 
compared with the other two cell subsets using the CSP transgenic system 
(Figure 3.21).  
Figure 3.21 CD14+ cells are similar to DC-SIGN+ MoDCs  in terms of cross-
presentation capacity.  
Mice were treated as described on Figure 2.16C. Mo-DCs were labeled either with MMD3 mAb 
in vivo or with anti-CD14 ex vivo, sorted as shown in the pseudocolor plots and used to stimulate 
CSP-specific CD8+ T cells labeled with CFSE. Data is representative of two independent 
experiments and error bars correspond to standard deviation of triplicate wells per condition. 
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 Thus monocyte differentiation to DCs in response to LPS requires CD14, 
which serves as an alternative marker to identify and isolate Mo-DCs from 
classical DCs. 
 
 
3.10. DC-SIGN is not required during Leishmania major infection 
  Mo-DCs have been shown to accumulate in the dermis and skin draining 
LNs in a murine experimental model of cutaneous leishmaniasis. These Mo-Dcs 
were involved in the inducion of protective Th1 responses (León et al., 2007). In 
line with this finding we wanted to address if DC-SIGN+ Mo-DCs were recruited 
to the skin draining lymph nodes during Leishmania major (L. major) infection. 
We studied the DC subpopulations present in the draining popliteal LNs at 
different time points after a high dose of parasites injected subcutaneously in the 
footpad. Figure 3.22A shows the kinetics in terms of cell numbers of total 
CD11c+ and also of the 3 distinct DC populations that we had defined in the LPS-
treated skin draining LNs during L. major infection. The total number of CD11c+ 
DCs increased between weeks 2 and 4 of the infection, mainly due to the 
expansion of the double negative cell subset. In contrast, DEC-205+ and DC-
SIGN+ DC subsets remained unchanged until week 2, but after this point the 
number of cells dropped markedly.  
Figure 3.22 DC-SIGN is not important during L. major infection 
Mice were infected s.c. with 1x106 parasites on the left footpad. (A) At different time points after 
the challenge, 10 µg of MMD3-Alexa 647 mAb was given i.v. 12 hr before the preparation of 
popliteal draining LNs cell suspensions. The total number of CD11c+ cells or from each DC subset 
was determine by FACS and calculate per million of cells acquired. (B) Footpad swelling was 
measured in WT and DC-SIGN KO mice (5-7 mice in each experimental group) in order to 
determine differences in the growth curve of the parasite in vivo. Line graph represents the mean 
± SD of lesion size at different time points after the challenge.  
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 We also compared the progression of the infection in DC-SIGN deficient 
and wild type control mice by weekly measuring the size of the lesion occurring 
at site of the parasite inoculation. The clinical course of infection was monitored 
for up to 8 weeks, during which the size of footpad lesion showed no differences 
between the two experimental groups (Figure 3.22B), with normal parasite 
clearance by KO mice.  
 Therefore, during an intracellular parasitic infection such as L. major, DC-
SIGN+ Mo-DCs are not expanded and DC-SIGN expression is not required for 
disease outcome and for parasite clearance.  
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Chapter 4. Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
! +,!
 More then 15 years of research since the findings by Sallusto and by 
Romani that monocytes can give rise to DCs in vitro, the concept of Mo-DCs as a 
specialized cell population formed under infectious and inflammatory conditions 
in vivo is becoming more clear. However, several gaps in the field have 
precluded detailed analysis of the phenotype and function of Mo-DCs, including 
the lack of markers that could specifically define these cells in the mouse. 
Therefore, the main finding that permitted our research was the derivation of new 
mAbs to the mouse DC-SIGN/CD209a (Cheong et al., 2010), a lectin receptor 
expressed on human Mo-DCs generated in vitro but not on classical dendritic 
cells (Geijtenbeek et al., 2000c). Much of this protein is expressed inside the cell 
and therefore difficult to detect by standard staining protocols.  
 First we show that, as in humans, also mouse DC-SIGN/CD209 is 
upregulated upon culture of bone marrow monocytes with GM-CSF and IL-4, 
concomitant with loss of the markers Ly6C and c-fms/CD115, that have been 
previously used to identify inflammatory monocytes in vivo. The Mo-DCs formed 
in vitro are dendritic cells in terms of their motility because they are nonadherent 
cells that continually form and retract processes in the living state, identical to the 
probing morphology of DCs in the T cell areas found in the lymphoid organs 
(Lindquist et al., 2004). 
 Using an ingenious in vivo labeling approach to mark DC-SIGN-
expressing cells directly in the mouse we found very few positive cells in the skin 
draining lymph nodes in the steady state. Strikingly, in mice systemically 
challenged with LPS, large numbers of cells expressing DC-SIGN rapidly appear 
in the paracortical T cell areas of lymph nodes. This niche is characteristic of 
DCs in lymphoid organs and an ideal position for clonal selection of antigen-
specific T cells from the recirculating repertoire. Any of the other TLR agonists 
tested was able to induce expansion of DC-SIGN+ cells. Importantly, when this 
newly recruited Mo-DCs were ex-vivo isolated are compared functionally to 
classical DCs from the same LNs, the former are not only active but can be 
superior in stimulating the MLR and can efficiently present and cross-present to 
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CD4+ and CD8+ T cells both soluble and cell-associated antigens that have been 
taken up in vivo.  
 A large emphasis has been placed on the superior cross-presenting 
activity of the CD8#+ or DEC-205+ subset of DCs (den Haan et al., 2000) (Schulz 
and Reis e Sousa, 2002) (Belz et al., 2004a). However, a widely held view is that 
CD8!+ DCs do not survey peripheral tissues but instead gain access to lymphoid 
organs like lymph nodes through the vasculature, giving rise to the term “lymph 
node resident DCs” for this population. In reality, we know very little about the 
trafficking patterns of these DCs, but if one assumes that CD8!+ DCs do in fact 
fail to patrol peripheral tissues, then a question is raised as how they gain access 
to antigens for cross-presentation. By comparison, other studies indicate that 
monocytes can mediate cross-presentation, raising another question as to 
whether more than one source of cell can mediate or is needed for cross-
presentation (Le Borgne et al., 2006). 
 A couple of recent studies have brought forward a model that might 
address both of these questions. Carbone, Heath, and co-workers show that 
CD8!+ DCs do not pick up tracers that mark migration from the periphery, but 
nonetheless they have a dominant role in presenting antigen deposited in 
peripheral tissue to CD8+ T cells during cross-priming (Belz et al., 2004b) (Allan 
et al., 2006). In these studies, they suggest that migratory DCs drive the 
response by transporting antigen from the periphery and then handing it off in a 
so-far uncharacterized form to CD8!+ DCs that carry out the presentation. If 
monocytes were the source of migratory DCs, they might be seen as playing an 
indirect role in cross-priming, acting mainly as antigen ferries. Nonetheless, this 
model is incompatible with a direct role of monocyte-derived cells and their own 
MHC I/peptide complexes in driving cross-priming as purposed by the work of Le 
Borgne et al., where MHC I-deficient monocytes were unable to promote cross-
presentation in a host where all other cells express MHC I appropriately. Our 
results also support the intrinsic capacity of Mo-DCs to promote cross-
presentation. 
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 In terms of function, we clear prove that Mo-DCs are equivalent in many 
respects to other DC subsets so far described, including in cross-priming, except 
that they are monocyte dependent, whereas numerous prior studies have shown 
that classical DCs are monocyte independent (Naik et al., 2006) and (Varol et al., 
2007) and derive from a committed pre-cDC in the bone marrow (Liu et al., 
2009).  
 Further studies using intravital microscopy combined with interventions to 
selectively deplete particular subsets of dendritic cells will be required to define 
the relative contributions of Mo-DCs to the induction of T cell proliferation and 
differentiation in vivo. 
 
 In order to define mechanisms underlying the differentiation of DC-SIGN+ 
cells we first show that bone marrow monocytes could give rise to Mo-DCs 
mobilized to the skin draining lymph nodes upon LPS stimulation in vivo. We also 
provide more direct evidence that DC-SIGN+ Mo-DCs are derived from 
monocytes using mice that express the diphtheria toxin receptor in cells of the 
monocyte/macrophage lineage. When mice were treated with diphtheria toxin 
DC-SIGN+ cells fail to accumulate in lymph nodes following LPS challenge.  
 On the other hand, expression of the receptor Flt3 is not required for the 
development of Mo-DCs. This result is in line with the phenotypic differences 
observed in terms of CD135 (Flt3 receptor) expression by the 3 populations of 
DCs in LPS treated lymph nodes, where the molecule is absent from DC-SGN+ 
cells (Figure 2.5F blue histogram on the top of the graph). All together these 
data, further corroborate the two current models for DC origin, posting the 
existence of two independent differentiation pathways: one dependent on Flt3 
responsible for the development and maintenance of the pool of classical DCs 
found in steady state conditions, in contrast with the GM-CSFR (CD115) 
signaling pathway that seems to be essential for the generation of DCs during 
inflammation, such as the bacterial stimuli given in our study.  
 Experiments designed to examine the turnover of the different DC 
populations in the LPS-treated LNs also support a monocyte origin of DC-SIGN+ 
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cells. Early DC progenitors in the BM, including MDPs have a high proliferative 
capacity (Fogg et al., 2006) (Waskow et al., 2008). However, this proliferative 
potential is lost with the commitment into more specialized cells. Monocytes are 
commonly considered to be non-proliferating cells that leave the bone marrow, 
circulate in the peripheral blood, and finally differentiate in the various tissues 
(Naik et al., 2006) (Varol et al., 2007) (Ginhoux et al., 2006). In contrast, pre-
DCs, maintain some proliferating activity although lower then MDP precursors, 
and both PDCs and cDCs in the peripheral lymphoid organs are able to divide in 
situ (Naik et al., 2006) (Liu et al., 2007). Therefore, in our experiments DEC-205+ 
and DEC-205- DCs were able to uptake BrDU whereas DC-SIGN+ Mo-DCs were 
not.  
  
 Another intriguing finding is that Mo-DCs are found only in peripheral 
lymph nodes but not in spleen or mesenteric lymph nodes. Other studies have 
shown that monocytes can be recruited to the spleen by macrophages infected 
with Listeria monoytogenes. There the monocytes develop into inflammatory 
dendritic cells that mediate protection from infection through production of tumor 
necrosis factor (TNF) and inducible nitric oxide synthase (iNOS) but do not 
contribute to induction of T cell responses (Serbina et al., 2003). It is possible 
that different gradients of chemokines and cytokines elicited in different tissues 
by microbial infection may determine the recruitment of monocytes and their 
differentiation into either inflammatory effector cells or antigen-presenting 
dendritic cells.  
 We also exclude the possibility of the spleen as a reservoir of precursor 
monocytes, as it has been suggested in response to ischemic myocardial injury, 
where undifferentiated monocytes accumulate in injured tissue and participate in 
wound healing in this animal model of heart attack (Swirski et al., 2009). This 
might be due to differences in the source of monocytes that are mobilized to the 
site of inflammation depending on the scenarios (e.g. pathogenic stimuli such as 
systemic LPS injection vs non-pathogenic such as myocardial injury).  
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 How do Mo-DCs reach lymph nodes? The conventional view is that 
monocytes first enter infected or inflamed non-lymphoid tissues where they 
capture antigen, mature, and subsequently migrate to the draining lymph nodes 
via the afferent lymph. This model was initially purposed by Randolph et al., 
where s.c. injection of latex microspheres reproduced an infection-mediated 
inflammatory process and could induce local differentiation of cutaneous 
inflammatory monocytes into DCs that subsequently migrated to the draining LNs 
(Randolph et al., 1999). In contrast, in our study we report that monocytes 
migrate into lymph nodes in a manner dependent on the cell adhesion molecule 
CD62L and the chemokine receptor CCR7, both expressed by bone marrow and 
blood monocytes, and consistent with a direct migration from blood through the 
high endothelial venules. Supporting this hypothesis is also the fact that blood 
monocytes drop to 20% of their normal levels 6–12 hr after i.v. LPS 
administration while they move to the LNs where they differentiate into DC-
SIGN/CD209a+ MMR/CD206+ Mo-DCs. Thus, the results implicate that possibly 
both pathways of monocytes migration and differentiation can occur and are 
dependent on the nature of the microbe and its route of entry. 
 Analysis of other chemokine receptor knockout strains pointed to a 
dispensable role of CCR5 and CCR6 but surprisingly to a partial dependence on 
CCR2. This data might suggest that CCR2 is involved at a more upstream level, 
i.e., the release of monocytes from the bone marrow into the bloodstream, as 
suggested by Serbina and Pamer in a model of Listeria monocytogenes infection. 
The authors showed that CCR2 is a key mediator in the control of bone marrow 
egress of monocytes into the blood but is not required for migration of these cells 
into the tissues (Serbina and Pamer, 2006).  
 A limitation in using chemokine KO mice for these studies is that receptor 
deficiency affects a wide variety of cells potentially implicated in inflammation. 
This is especially important in the case of CCR7, a pivotal chemokine receptor in 
the migration of immune cells into lymph nodes, and that is expressed not only 
be migratory DCs, but also by naive T cells. In addition to naive T cells, 
regulatory and central memory T cells migrate to lymph nodes via CCR7 (Forster 
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et al., 2008). More recently, expression of CCR7 by neutrophils was shown to be 
required for their relocation into secondary lymphoid organs (Beauvillain et al., 
2011). Consequently, the whole inflammatory climate is affected in CCR7 
deficient mice so that it becomes practically impossible to distinguish direct from 
indirect effects of chemokine receptor deficiency on DC trafficking.  
 In this study, we circumvent this problem by creating chimeric mice with 
mixed bone marrow containing both WT and chemokine receptor KO donor cells. 
This allowed us to specifically track and compare, within the same animal, KO vs 
control (WT) cell populations in the blood and in the skin draining Lymph nodes. 
Meanwhile, sufficient immunocompetent cells were present to sustain an 
inflammatory environment. Using this approach, we found that Mo-DCs 
themselves need to express CCR7 in order to differentiate and migrate to the 
skin draining LNs upon LPS inflammation, and discards the possibility that the 
absence of CCR7 on another cell type indirectly affects Mo-DCs trafficking. Apart 
from directing cell migration, CCR7 is also important in the regulation of DC 
survival (Sánchez-Sánchez et al., 2004). Therefore, it is significant to speculate 
that the phenotype observed in the absence of CCR7 during our study can be 
due to cell death of Mo-DCs right after differentiation and maturation with LPS 
instead of failure in the recruitment to the skin draining lymph nodes.    
  
 We have also identified a new molecular pathway of DCs differentiation in 
which monocyte migration to lymph nodes and differentiation into potent antigen-
presenting cells is elicited by administration of LPS or gram-negative bacteria, 
but not by administration of other Toll-like receptor (TLR) agonists or gram-
positive bacteria. In spite of hundreds of studies of the response of mice to LPS, 
this mobilization of antigen-presenting cells was not previously appreciated.  
 To support and explain the peculiar role of TLR4 agonists, we examined 
gene expression for several TLRs. Whereas DEC-205+ DCs expressed TLR3 
and pure monocytes from the bone marrow expressed many other TLRs, only 
TLR4 increased markedly when monocytes differentiated into Mo-DCs in culture 
or in vivo. This was also the case for the CD14.  
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 CD14 is found in two forms: a soluble form (sCD14), which occurs in the 
plasma, and a membrane-associated form that exists attached to the surface of 
myeloid cells via a glycosylphosphatidyinositol tail. Therefore, in the past, CD14 
was simply viewed as a marker molecule for monocytes and macrophages. The 
discovery that it can function as a receptor for LPS has changed the concepts of 
its role in the physiology of myeloid cells. CD14 was then thought to be the long 
sought after receptor for LPS, as antibodies to CD14 abrogated the binding of 
LPS/LBP (Wright et al., 1990). However and because CD14 anchors without a 
transmembrane domain it was always unlikely that CD14 alone could convey a 
signal in response to LPS. Subsequent studies have revealed that the actual 
receptor for LPS is TLR4 (Poltorak et al., 1998).  Since this discovery, studies on 
CD14 have focused on the role of CD14 in TLR4 signaling cascade, which is 
MyD88-independent and Trif-dependent (Jiang et al., 2005). In our study we 
show that CD14 is a key feature of the Mo-DCs that are mobilized by LPS, and 
can be used as an alternative marker for DC-SIGN+ DCs and is also essential for 
their expansion.  
 
 Although DC-SIGN/CD209a was critical for identifying authentic Mo-DCs 
in vivo, functions for this lectin need research. We showed, for example, that DC-
SIGN#/# monocytes become Mo-DCs (marked by MMR/CD206 or CD14) in the 
T cell areas, just like WT, when the mice are given LPS (Figure 2.7). Therefore 
DC-SIGN seems not to be involved in Mo-DC mobilization and differentiation. 
Several studies have shown that DC-SIGN/CD209a can play pathogenic roles, 
either in transmitting infectious agents like HIV and CMV in the case of cultured 
human MoDCs (Geijtenbeek et al., 2000b) and (Halary et al., 2002) or in 
transducing inhibitory signals as seen when human DC-SIGN/CD209 interacts 
with mycobacteria (Geijtenbeek and van Kooyk, 2003) (Tailleux et al., 2003). DC-
SIGN/CD209 could also have protective functions for capture and presentation of 
glycan-modified antigens (Tacken et al., 2005). It was also shown that 
Leishmania amastigotes could bind specifically and with high avidity to DC-SIGN 
expressed on human monocyte-derived dendritic cells obtained from in vitro 
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cultures, suggesting a role for this receptor in the outcome of the immune 
responses against this intracellular parasitic infection (Colmenares et al., 2002). 
However, we could not detected DC-SIGN+ cells during the course of the 
infection using an experimental murine model of leishmaniasis. In addition, DC-
SIGN expression on DCs is dispensable for the control of L. major infection in 
vivo. At face value, our results appear to contradict previous studies arguing that 
Leishmania major parasites induce differentiation of Mo-DCs with important roles 
in the induction of Th1 responses against the parasite at the site of infection 
(León et al., 2007). However, in this previous study, Mo-DCs were mainly defined 
by expression of Ly6C, a marker not found on the LPS-mobilized DC-SIGN+ cells 
described in this study. The usefulness of the markers used in different studies to 
define Mo-DCs cannot be overemphasized, and just might reflect the extensive 
heterogeneity and functional specialization of dendritic cells. 
  
 Thus we would like to propose that the mobilization of Mo-DCs described 
here has two roles. One is part of the innate response to gram-negative bacteria 
and other agents that contain agonists for the TLR4-CD14 complex, although this 
will require additional studies of the functional properties of Mo-DCs such as the 
production of cytokines and chemokines. A second is as a segue to the adaptive 
immune response. During the TLR4-based response, Mo-DCs increase while 
classical DCs decrease, so that Mo-DCs become the dominant cell for induction 
of effective and combined CD4+ and CD8+ T cell immunity, with or without the 
requirement for bacterial replication in this newly mobilized DC reservoir. 
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Chapter 5. Conclusions and Future 
perspectives 
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The original work described in this thesis dissertation lead to important 
advances in the establishment of monocytes as direct precursors of DCs in 
vivo.  The main novelties of this work are listed below. (Figure 5.1) 
1. We describe valuable markers for Mo-DCs, DC-SIGN, mannose receptor 
and CD14, which were never previously used. 
2. We show that Mo-DCs are phenotypically and functionally “authentic” DCs 
and are as effective as classical DCs at both MHCI and II presentation 
including in vivo assays for antigen capture. 
3. We uncover a distinct role for TLR4 signaling; literally thousands of papers 
have injected LPS into mice and no one has reported that monocytes in 
large numbers convert into authentic DCs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Model proposed with this work.  
Blood monocytes rapidly and fully differentiate into skin draining lymph node DCs or Mo-DCs. 
The stimulus is gram-negative bacteria or lipopolysaccharide via TLR4, CD14, and Trif. DC-
SIGN/CD209a, MMR/CD206 and CD14 expression marks the Mo-DCs. Mo-DCs are as potent as 
classical DCs for presenting proteins on MHC I (CD8+ T cells) and MHC II (CD4+ T cells). 
 
! ","!
 This study also contributes to an increasingly detailed picture of how 
dendritic cells are derived and add a new branch to the work recently published 
by Liu at al. (Liu et al., 2009) clarifying the different types of dendritic cells and in 
particular the point at which classical dendritic cells separate from the closely 
related monocytes, even though they share a common ancestor in the bone 
marrow, the MDP (Figure 5.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 Summary of DC development under steady state (blue and 
orange paths) or inflammatory conditions (red pathway) 
 
 At the moment we do not have yet a clear answer to address where the 
conversion of monocytes into Mo-DCs take place in vivo. The detailed tracking of 
these cells may require additional tools such as a mouse model with a 
fluorescent reporter gene (e.g. GFP) under the control of DC-SIGN promoter, or 
by using multiphoton real-time microscopy in order to track DC-SIGN labeled 
cells in vivo.  
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 Understanding the genetic program and the molecular mechanisms that 
govern the mobilization of these Mo-DCs will open way to new and highly specific 
vaccination strategies, given the powerful antigen presentation and immune 
stimulatory consequences of this full DC differentiation pathway. Therefore, it will 
be also important to address the role of the Mo-DCs here described in the 
context of clinically relevant bacterial infections (e.g. Salmonella). 
 Although this work was performed in mice, the discovery that real dendritic 
cells can be coaxed from blood monocytes promises to accelerate the study of 
dendritic cells in humans, because it is much simpler clinically to culture 
monocytes from a blood sample than prepare dendritic cells from lymph tissues.  
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